(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007556 A1

(51) International Patent Classification[7]: C07K 19/00, A61K 39/00, 39/245, 39/29

(21) International Application Number: PCT/AU2003/000910

(22) International Filing Date: 14 July 2003 (14.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002950183 12 July 2002 (12.07.2002) AU

(71) Applicants *(for all designated States except US)*: **CSL LIMITED** [AU/AU]; 45 Poplar Road, PARKVILLE, Victoria 3052 (AU). **THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH** [AU/AU]; 300 Herston Road, HERSTON, Queensland 4029 (AU).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **WEBB, Elizabeth, Ann** [AU/AU]; 36 Zig Zag Road, ELTHAM, Victoria 3095 (AU). **SCHOOFS, Peter** [AU/AU]; 5 MacBean Court, Greenvale, Victoria 3405 (AU).

(74) Agent: **BLAKE DAWSON WALDRON PATENT SERVICES**; Level 39, 101 Collins Street, MELBOURNE, Victoria 3000 (AU).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *with amended claims*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/007556 A1

(54) Title: EXPRESSION OF HYDROPHOBIC PROTEINS

(57) Abstract: Methods are disclosed for the design of non-native (*i.e.* heterologous) polypeptides comprising a proportion of hydrophobic amino acids which have an increased probability of being efficiently expressed in an expression system such as a bacterial host (*e.g. E. coli*). The methods involve identifying one or more hydrophobic peptide sequences within a polypeptide of interest, and arranging or re-locating at least one of the hydrophobic peptide sequences within said polypeptide so as to generate a candidate polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s). Such methods are particularly useful for designing polyepitope polypeptides, and specific examples of such are described for Epstein-Barr virus (EBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

EXPRESSION OF HYDROPHOBIC PROTEINS

Field of the Invention:

This invention relates to the expression of non-native (ie heterologous) polypeptides which comprise a proportion of hydrophobic amino acids in an expression system such as a bacterial host (eg *E. coli*). In particular, the invention provides a method for designing polyepitope polypeptides with an increased probability of being efficiently expressed (ie in amounts detectable by SDS-PAGE). One particular application of the invention relates to the production of a polyepitope polypeptide comprising cytotoxic T-cell lymphocyte (CTL) epitopes from Epstein-Barr virus (EBV) for use in a polyepitope vaccine capable of eliciting a CTL immune response for the prevention of diseases associated with EBV (eg infectious mononucleosis (IM) and nasopharyngeal carcinoma (NPC)). Other particular applications relate to the production of polyepitope polypeptides suitable for use in polyepitope vaccines for preventing and/or treating hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Background of the Invention:

In order to maximise production of recombinant polypeptides in a bacterial host (eg *E. coli*), a number of parameters can be considered including factors affecting transcription (eg promoter choice, etc) and factors affecting translation mechanisms such as minimising the use of rare codons. However, these are unlikely to have an impact on the production of recombinant polypeptides comprising stretches of hydrophobic amino acids, which have traditionally proven difficult to produce in recombinant bacterial expression systems. Indeed, in the case of polypeptides comprising transmembrane sequences, the removal of these hydrophobic sequences generally improves yields of the recombinant molecule (Frace et al, 1999; Hobman et al, 1994; Polte et al, 1991; EMBL website-protein toxicity: www.embl-heidelberg.de/ExternalInfo).

The most likely reason for problems occurring in the production of foreign polypeptides possessing regions of hydrophobicity (particularly those with non-native sequences such as fusion proteins), is the post-translational association of nascent polypeptides with chaperone proteins such as *E. coli* groEL. GroEL is involved in the refolding process of polypeptides emerging from the ribosome and proteins will recycle through the chaperone system until the correct conformation is achieved or the protein is

targeted for degradation. GroEL is known to bind hydrophobic amino acids and part of the refolding process is essentially to bury these hydrophobic sequences within the interior of the protein (Fisher and Yuan, 1994; Zahn and Pluckthun, 1994; Hayer-Hartl et al, 1994; Richarme and Kohiyama, 1994; Hendrick and Hartl, 1995; Lin et al, 1995).

Polyepitope or "polytope™" constructs (ie polypeptides comprising a tandem array of epitopes which may be contiguous or otherwise spaced apart by short intervening amino acid sequences of, for example, 1 to 5 amino acids in length), would be expected to be inherently unable to internalise any hydrophobic regions as they are not naturally-occurring sequences and lack the folding capabilities inbuilt in naturally-occurring proteins. Hence polypeptides which consist of non-native sequences, particularly those with a high proportion of hydrophobic amino acids, are likely to be sequestered in the chaperone folding pathway and ultimately targeted for degradation if a certain degree of conformational stability cannot be achieved.

Polyepitope vaccines typically comprise one or more polypeptides each made up of a tandem array of CTL epitopes. These CTL epitopes, particularly those of the HLA A2 type, often comprise predominantly hydrophobic amino acids and since HLA A2 is represented in over 40% of the human population it is mandatory that these epitopes be included in any effective polyepitope vaccine formulation.

Examples of polyepitope vaccines are described in Australian Patent No. 736336, the entire disclosure of which is to be regarded as being incorporated herein by reference. In this patent, vaccines are described which comprise a synthetic or recombinant polypeptide, or a recombinant vaccinia virus or DNA vaccine encoding same, wherein the synthetic or recombinant polypeptide typically comprises a tandem array of CTL epitopes (eg a tandem array of 2 to 10 CTL epitopes) wherein at least two of the CTL epitopes are contiguous or spaced apart by intervening sequences in which the intervening sequences do not comprise any substantial lengths of naturally occurring flanking sequences of the epitopes. Particularly described in the prior patent are vaccines comprising a polyepitope vaccinia virus encoding a polyepitope polypeptide comprising nine CTL epitopes (each CTL epitope being of 9 to 10 amino acids in length) from EBV. Standard chromium release assays conducted with this virus in a panel of target cells expressing the HLA alleles for restriction of each epitope and using autologous CTL clones specific for each epitope as effector cells, showed that each epitope could be efficiently processed from the polyepitope polypeptide since, in all cases, the CTL clones recognised and killed the HLA matched

target cell infected with the polyepitope vaccinia virus, but did not kill any of the negative controls (ie TK-vaccinia).

Further examples of polyepitope vaccines are described in International patent specification WO 01/47541, the entire disclosure of which is to be regarded as being incorporated herein by reference. In this specification, vaccines are described which comprise multiple HLA epitopes wherein the multiple HLA epitopes have been sorted so as to minimise the number of "junctional epitopes" (ie epitopes inadvertently created by the juxtaposition of two other epitopes) and wherein flanking amino acid residues are introduced wherever junctional epitopes are unavoidable.

Polyepitope vaccines may include a large number of CTL epitopes (eg 10 or more) so that the HLA diversity of the target population is covered. It has therefore been contemplated by the present applicants to produce an EBV polyepitope vaccine which includes EBV epitopes restricted by HLA A2, A3, A11, A23, A24, B7, B8, B27, B35, B44, B46, B57, B58, B60 and B62, so as to provide protection against EBV in over 90% of the human population. This would involve the incorporation of about 26 EBV CTL epitopes into a polyepitope polypeptide. For the reasons given above, it was expected that such a polypeptide would contain hydrophobic regions and that expression in a suitable host could be highly problematical.

The work leading to the present invention was aimed at elucidating a method or procedure for overcoming the difficulties of expressing non-native polypeptides which comprise a proportion of hydrophobic amino acids (eg polyepitope polypeptides) in a bacterial host such as *E. coli*. The present applicants have, as a result of that work, identified a novel method for designing candidate polyepitope polypeptides with an increased probability of being efficiently expressed in a bacterial host and/or yielding a purified polyepitope polypeptide which is soluble in aqueous solutions. The identification of this method arose out of a recognition of a need for individual epitopes to be arranged in a non-random way within a polyepitope polypeptide so that regions of hydrophobicity are distributed more evenly throughout the molecule rather than clustered in one or more particular regions. The novel method therefore involves identifying one or more hydrophobic peptide s equences within a polypeptide and arranging or re-locating at least one of the hydrophobic peptide sequence(s), so as to; (a) reduce or minimise amplitude (ie peaks) in hydrophobicity across the length of the polypeptide, and/or (b) reduce or minimise the total length of any hydrophobic region(s) within the polypeptide. To assist in the utility of this method, the present applicants have also identified an algorithm which

permits any number of epitopes to be readily ordered into a polyepitope polypeptide sequence lacking or having reduced regions of relative high hydrophobicity.

Summary of the Invention:

In a first aspect, the present invention provides a method for designing a candidate polypeptide for expression in a prokaryotic or eukaryotic host, said method comprising,

identifying one or more hydrophobic peptide sequences within a polypeptide of interest, and

arranging or re-locating at least one of said hydrophobic peptide sequences within said polypeptide so as to generate said candidate polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s).

Preferably, the polypeptide of interest is non-native to the intended host. Since the most preferred host is *E. coli*, most preferably the polypeptide is non-native to *E. coli*.

The polypeptide of interest will preferably be a non-natural polypeptide or even a theoretical non-natural polypeptide (ie a polypeptide yet to be synthesised or expressed) comprising a plurality of amino acid sequences of interest some of which may be hydrophobic or suspected to be hydrophobic, and which has been found not to be, or is suspected not to be, efficiently expressed in said host. For such a polypeptide of interest, the method of the first aspect provides the possibility of identifying one or more hydrophobic peptide sequences, if any, within the polypeptide of interest and arranging or re-locating at least one of the hydrophobic peptide sequence(s) so as to generate a candidate polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s), and therefore an increased probability of being efficiently expressed in a suitable host.

Preferably, the polypeptide of interest may be a synthesised or theoretical polyepitope polypeptide comprising a tandem array of epitopes of interest (eg CTL epitopes, which, as is mentioned above, often predominantly comprise hydrophobic amino acids). For such a polypeptide of interest, the method of the first aspect permits the design of candidate polyepitope polypeptides comprising a large number of epitopes of interest (eg 5 to 100 or more) with an increased probability of being efficiently expressed in a suitable host, by enabling the possibility of identifying one or more hydrophobic epitopes and arranging or re-locating at least one of the hydrophobic epitope(s), so as to generate a candidate polyepitope polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s).

It has been found that the method of the first aspect is best applied to the design of a candidate polyepitope polypeptide in a manner which identifies and ranks the relative hydrophobicity of each of the selected epitopes (nb The epitopes of interest may be a range of epitopes from a single pathogen (eg EBV) selected to provide a polyepitope polypeptide that covers the HLA diversity of the target population. The epitopes of interest may also be one or more epitopes from a range of pathogens or the epitopes may be derived from a non-microbial source such as a tumour cell for treating or preventing cancer.), groups the ranked epitopes into three groups of substantially equivalent numbers, based upon the identified relative hydrophobicity (ie so as to produce the groups, Group 1 = most hydrophobic, Group 2 = middle hydrophobicity, and Group 3 = least hydrophobic and "residual" epitopes where the total number of epitopes (N) is not wholly divisible by 3), and then arranges the epitopes into triplets where the triplets contain an epitope from each group (ie three linked epitopes; epitope 1 - epitope 2 - epitope 3) and arranged into a candidate polyepitope polypeptide having the formula, Triplet 1 - Triplet 2 - .... - Triplet N/3, as follows:

	Epitope 1	Epitope 2	Epitope 3
Triplet 1 (N-terminal)	Most hydrophilic of Group 2	Most hydrophobic of Group 1	Most hydrophilic of Group 3
Triplet 2	2nd most hydrophilic of Group 2	2nd most hydrophobic of Group 1	2nd most hydrophilic of Group 3
Triplet N/3 (C-terminal)	Most hydrophobic of Group 2	Most hydrophilic of Group 1	Most hydrophobic of Group 3

(Any "leftover" epitope(s) (ie least hydrophilic epitope(s) of Group 3) may be added to the C-terminal of Triplet N/3, or otherwise may be located within the candidate polyepitope polypeptide sequence so as to reduce any local peaks of hydrophobicity.)

Between the epitope triplets, or between any or all of the epitopes within a triplet, there may be intervening sequences (preferably short sequences of 1 to 10 amino acids) which may optionally be hydrophilic (eg lysine-lysine) so as to reduce any local peaks of hydrophobicity. Preferably, the epitopes within a triplet are contiguous.

Other simple methods for arranging the epitope(s) so as to minimise extremes in hydrophobicity in a polyepitope polypeptide will be readily apparent to persons skilled in the art, and are to be considered as forming part of the present invention. For example, in

one variation of the above method, and referring again to Table 1, epitope 1 would instead be selected using the stated criteria for epitope 2, epitope 2 would instead be selected using the stated criteria for epitope 3, and epitope 3 would instead be selected using the stated criteria for epitope 1. In another variation, the epitopes would be selected from four groups of ranked epitopes and consequently arranged into sets of 4 epitopes.

As mentioned above, the method of the first aspect generates a candidate polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s). In the context of applying the method to a natural polypeptide, "reduced amplitude in hydrophobicity" is to be understood to mean that any peaks of hydrophobicity of the candidate polypeptide (ie as may be calculated/measured using Pinsoft 2 from Mimotopes Pty Ltd, Melbourne, Australia) is reduced relative to the natural polypeptide, and that "reduced length of any hydrophobic region(s)" is to be understood to mean that the length of amino acid sequence of any hydrophobic region(s) in the candidate polypeptide is/are reduced relative to the natural polypeptide. In the context of applying the method to a non-natural polypeptide (including a theoretical non-natural polypeptide), "reduced amplitude in hydrophobicity" is similarly to be understood to mean that any peaks of hydrophobicity of the candidate polypeptide (ie as may be calculated/measured using Pinsoft 2 from Mimotopes Pty Ltd) is reduced relative to the non-natural polypeptide, and that "reduced length of any hydrophobic region(s)" is to be understood to mean that the length of amino acid sequence of any hydrophobic region(s) in the candidate polypeptide is/are reduced relative to the non-natural polypeptide. In the context of applying the method to the more specific non-natural polypeptide example of a polyepitope polypeptide, "reduced amplitude in hydrophobicity" is to be understood to mean that any peaks of hydrophobicity of the candidate polypeptide (ie as may be calculated using the mathematical expression described below) is reduced relative to most of the possible random arrangements of the epitopes comprising the polyepitope polypeptide, and that "reduced length of any hydrophobic region(s)" is to be understood to mean that the length of amino acid sequence of any hydrophobic region(s) in the candidate polypeptide is/are reduced relative to most of the possible random arrangements of the epitopes within the polyepitope polypeptide.

Once a candidate polypeptide has been designed in accordance with the method of the first aspect, a polynucleotide encoding the candidate polypeptide may be synthesised according to any of the methods well known to persons skilled in the art. The encoding polynucleotide may be incorporated into, for example, vectors such as viral vectors (eg

vaccinia to provide a recombinant polyepitope viral vaccine) or expression vectors such as those suitable for expression in a suitable host.

Thus, in a second aspect, the present invention provides a method of expressing a polypeptide in a suitable host, said method comprising,

designing a polypeptide in accordance with the method of the first aspect,

introducing a polynucleotide encoding said polypeptide into said host, such that said host is capable of expressing said polypeptide, and

culturing said host under conditions suitable for expression of said polypeptide.

The expressed polypeptide may be isolated by, for example, lysing the host cell and purifying the polypeptide from the produced cell lysate.

The polynucleotide introduced into the host cell may encode the polypeptide in the form of a fusion of the polypeptide with a suitable carrier protein. Alternatively, the polypeptide could be expressed and subsequently linked to or otherwise associated with a suitable carrier protein. Suitable carrier proteins are well known to persons skilled in the art and include β-galactosidase, glutathione S-transferase and the gp350 structural protein from EBV or a fragment thereof. The carrier protein may comprise additional useful epitopes. Further increases in expression benefits provided by ordering may be conferred by the carrier protein.

In a third aspect, the present invention provides a polypeptide designed in accordance with the method of the first aspect.

If desired, the polypeptide of the third aspect may be in the form of a fusion of the polypeptide with a suitable carrier protein.

In a fourth aspect, the present invention provides a polyepitope polypeptide designed in accordance with the method of the first aspect.

If desired, the polypeptide of the fourth aspect may be in the form of a fusion of the polypeptide with a suitable carrier protein.

In a fifth aspect, the present invention provides a polyepitope polypeptide comprising N epitopes, wherein N is any integer (preferably an integer in the range of 5 to 100, and more preferably, 10 to 35), said polyepitope polypeptide having the formula;

Triplet 1 - Triplet 2 - .... - Triplet N/3,

wherein each of said triplets comprises three linked epitopes selected by,

identifying and ranking the relative hydrophobicity of each of the N epitopes,

grouping the ranked N epitopes into three groups of substantially equivalent numbers, based upon the identified relative hydrophobicity of the N epitopes, to produce a

first group (ie Group 1) comprising the most hydrophobic epitopes, a second group (ie Group 2) comprising the epitopes having a middle level of hydrophobicity, and a third group (ie Group 3) comprising the least hydrophobic epitopes, and

selecting the epitopes for each of said triplets according to the following table:

	Epitope 1	Epitope 2	Epitope 3
Triplet 1 (N-terminal)	Most hydrophilic of Group 2	Most hydrophobic of Group 1	Most hydrophilic of Group 3
Triplet 2	2nd most hydrophilic of Group 2	2nd most hydrophobic of Group 1	2nd most hydrophilic of Group 3
Triplet N/3 (C-terminal)	Most hydrophobic of Group 2	Most hydrophilic of Group 1	Most hydrophobic of Group 3

Preferably, the first, second and third groups comprise identical numbers of epitopes. Where N is an integer not wholly divisible by 3 (ie an integer other than, for example, 6, 9, 12, 15, and 18), then the residual epitopes are preferably included within the third group.

At the end of the step of selecting epitopes for each of said triplets, if there is/are any leftover epitope(s) (ie least hydrophilic epitope(s) of Group 3), then this/these may be added to the C-terminal of Triplet N/3, or otherwise may be located within the candidate polyepitope polypeptide sequence so as to reduce any local peaks of hydrophobicity.

Between the epitope triplets, or between any or all of the epitopes within a triplet, there may be intervening sequences (preferably short sequences of 1 to 10 amino acids) which may optionally be hydrophilic (eg lysine-lysine) so as to reduce any local peaks of hydrophobicity, or otherwise avoid the creation of junctional epitopes. Preferably, the epitopes within a triplet are contiguous.

If desired, the polyepitope polypeptide of the fifth aspect may be in the form of a fusion of the polyepitope polypeptide with a suitable carrier protein.

In a sixth aspect, the present invention provides a polypeptide vaccine comprising a polyepitope polypeptide according to the fourth or fifth aspect and a pharmaceutically acceptable carrier and/or adjuvant.

In a seventh aspect, the present invention provides a polyepitope polypeptide comprising an amino acid sequence substantially corresponding to an amino acid sequence selected from the group consisting of:

FLRGRAYGL – PYLFWLAAI – HRCQAIRKK – RRIYDLIEL – VQPPQLTLQV-GLCTLVAML - RLRAEAQVK -IEDPPFNSL –YLLEMLWRL – GQGGSPTAM - AVLLHEESM - IALYLQQNWWTL-RAKFKQLL - SSCSSCPLSKI- TYGPVFMCL-QAKWRLQTL - RPPIFIRRL- VSFIEFVGW - YPLHEQHGM –VEITPYKPTW - CLGGLLTMV – EENLLDFVRF - TYSAGIVQI – LLDFVRFMGV -EGGVGWRHW (SEQ ID NO:1),

FLRGRAYGL - PYLFWLAAI – HRCQAIRKK – RRIYDLIEL – GLCTLVAML – RLRAEAQVK - IEDPPFNSL –TYSAGIVQI - LLDFVRFMGV - EGGVGWRHW - IALYLQQNWWTL - RAKFKQLL – SSCSSCPLSKI - TYGPVFMCL - QAKWRLQTL-RPPIFIRRL - VSFIEFVGW – YPLHEQHGM – VEITPYKPTW – CLGGLLTMV – EENLLDFVRF - YLLEMLWRL – GQGGSPTAM - AVLLHEESM – VQPPQLTLQV (SEQ ID NO:2),

SSCSSCPLSKI – HRCQAIRKK – CLGGLLTMV – LTAGFLIFL – RLRAEAQVK – IEDPPFNSL – LLSAWILTA – RRRWRRLTV - PYLFWLAAI – YLLEMLWRL – GQGGSPTAM – VMSNTLLSAW – ALLVLYSFA – RAKFKQLL – IALYLQQNW – TYGPVFMCL - QAKWRLQTL – YLQQNWWTL – YPLHEQHGM – CPLSKILL (SEQ ID NO:3),

IPIVAIVALV – RLRPGGKKK – ILKEPVHGV – PLVKLWYQL – RPGGKKKYKL – KYKLKHIVW – TWETWWTEYW – EIKDTKEAL – KRWIILGLNK - KLWVTVYYGV – KIEELRQHL – MTNNPPIPV – VTLWQRPLV – WASRELERF – LLWKGEGAV – YTAFTIPSI – IYQEPFKNLK – SLYNTVATL – AIIRILQQL – AIFQSSMTK – VIYQYMDDL – LVGPTPVNI – TPQDLNTML – YLAWVPAHK – ALVEICTEM – TLNAWVKVV (SEQ ID NO:4),

and

LLFNILGGWV – KTSERSQPR – FLLLADARV – LLFLLLADA – RLGVRATRK – GVAGALVAFK – LPGCSFSIF – RMYVGGVEHR – VAGALVAFK – DLMGYIPLV – LIFCHSKKK – ILAGYGAGV – HMWNFISGI – QLFTFSPRR – VGIYLLPNR – FWAKHMWNF – YLVTRHADV – LSAFSLHSY – WMNRLIAFA – YLLPRRGPRL –

YLVAYQATV – RLIVFPDLGV – TLGFGAYMSK – IPFYGKAI – VLVGGVLAA – CTCGSSDLY (SEQ ID NO:5).

In an eighth aspect, the present invention provides a polyepitope vaccine comprising a polyepitope polypeptide according to the seventh aspect and a pharmaceutically acceptable carrier and/or adjuvant.

Detailed Description of the Invention:

The present applicants have identified novel methods for designing a candidate polyepitope polypeptide, with an increased probability of being efficiently expressed in a prokaryotic or eukaryotic host (ie in amounts detectable by SDS-PAGE). The method involves identifying one or more hydrophobic epitope(s) and arranging or re-locating at least one of the hydrophobic epitope(s) so as to generate a candidate polyepitope polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s).

An algorithm to calculate hydrophobicity values of amino acid sequences and subsequently arrange sequences to; (a) reduce or minimise amplitude in hydrophobicity, and/or (b) reduce or minimise the length of hydrophobic sequences, was generated and initially applied to 26 CTL epitope sequences from EBV. This resulted in the design of two initial candidate polyepitope polypeptides (designated PT26A and PT26B, described hereinafter), one of which proved to be efficiently expressed in *E. coli*. The expressed polyepitope polypeptide shows promise as the basis of an EBV vaccine for prevention or treatment of infectious mononucleosis and/or EBV-related cancers such as Burkitts lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma, nasopharyngeal carcinoma, gastric adenocarcinoma, lymphomas associated with immunosupression, lymphoepithelioma-like carcinomas, and immunodeficiency-related leiomyosarcoma.

While looking for an explanation as to why the expression capabilities of *E. coli* for the two similar candidate polyepitope polypeptides were different, summations of hydrophobicity values (designated Hydrophobic Index (HI) values) were calculated for different numbers of epitopes over the length of the candidate polyepitope polypeptides to identify local areas of hydrophobicity. Summation over 3 and 4 epitopes showed that there were regions in the non-expressed polypeptide where the HI value was higher than in the expressed polypeptide. This information enabled the identification of a threshold HI value, such that polypeptide sequences which comprised a region with an HI value in

excess of the threshold value, could be predicted as being less likely of being efficiently expressed in a bacterial host.

Thus, in a preferred embodiment of the methods of the present invention for designing candidate polypeptides, the methods involve initially calculating hydrophobicity values and arranging peptide sequences to; (a) reduce or minimise amplitude in hydrophobicity, and (b) reduce or minimise the length of hydrophobic sequences; and then "fine-tuning", if necessary, by calculating the HI values over different peptide sequence groups, thus providing numerical values for comparison and prediction of the likelihood of a candidate polypeptide sequence being efficiently expressed in a bacterial host. So, in applying this preferred embodiment to the design of a candidate polyepitope polypeptide, the method involves:

(i) Calculating the hydrophobic value for each epitope using a suitable algorithm (eg Fauschere and Pliska, 1983 contained within the software package "Pinsoft 2" from Mimotopes Pty Ltd).

(ii) Ranking the set of epitopes in order of decreasing hydrophobicity.

(iii) Dividing the rank ordered set of epitopes into a number of equal groups (eg three equal groups wherein group 1 = most hydrophobic, group 2 = middle hydrophobicity and group 3 = least hydrophobic (most hydrophilic)), and including any residual epitopes in the most hydrophilic group.

(iv) Creating sets (eg triplets) of epitopes by taking, in for example a case where the epitopes have been divided into three groups, the most hydrophilic epitope of group 2 (ie last in group 2), then the most hydrophobic epitope (ie number 1 in group 1) and lastly the most hydrophilic epitope (ie last in group 3) until all epitopes in groups 1 and 2 have been used (nb "Leftover" epitopes are handled as set out in step (ix) below).

(v) Arranging the sets of epitopes (eg triplets) into a sequence in the order in which they were produced (eg Triplet 1 - Triplet 2 – Triplet 3 – etc).

(vi) Plotting the hydrophobicity of the arranged polyepitope polypeptide sequence using a suitable algorithm (eg Fauschere and Pliska, 1983, or Hopp and Woods, 1981).

(vii) If necessary, reducing hydrophobic amplitude by re-locating sets of epitopes (eg triplets) from areas of low hydrophobicity into areas of high peak hydrophobicity and/or by re-locating individual hydrophobic (ie group 1) epitopes from areas of peak hydrophobicity into areas of low hydrophobicity.

(viii) Re-calculating the hydrophobicity plots and continuing, if necessary, to shuffle sets of epitopes (eg triplets) as in step (vii) above to generate a final sequence arrangement.

(ix) Placing any leftover epitopes (eg least hydrophilic epitopes of group 3) at the C-terminal of the final sequence arrangement or other location so as to further reduce local peaks in hydrophobicity (ie by inserting them adjacent to epitopes of peak hydrophobicity).

(x) Placing any affinity tags (usually hydrophilic, eg a hexa-histidine sequence) at either the N- or C- terminal of the final polyepitope polypeptide sequence or at the C-terminal if the final polyepitope polypeptide sequence is to be expressed as a fusion protein.

The HI values may be calculated by using the mathematical expression:

$$HI_m = \sum_{e=m}^{e=m+n-1} x_e$$

(where m = group number, n = group size, e = integer (epitope) number, x = epitope hydrophobicity value).

Preferably, the HI values are calculated using this mathematical expression when n=3 and n=4. In the examples provided hereinafter, this calculation predicted that to be able to express linked, random, short amino acid sequences in *E. coli* in SDS-PAGE detectable amounts, the hydrophobic index over groups of three epitope sequences would need to be less than 1.8 ($HI_3 < 1.8$) and/or that over groups of four epitope sequences, the hydrophobic index would need to be less than 2.5 when x was calculated using Pinsoft 2 (Mimotopes Pty Ltd) and specifying the N-terminus as N-acetyl and the C-terminus as carboxy amide. Different cut-off values will be obtained with different hydrophobicity algorithms.

It will be readily appreciated that the calculation of HI values in this manner, would be useful for predicting whether a natural, non-bacterial polypeptide or a derivative thereof may be efficiently expressed in *E. coli*. The present invention therefore further extends to a method of predicting efficient expression of a polypeptide in a suitable host (eg a bacterial host), involving calculating HI values in accordance with the mathematical expression:

$$HI_m = \sum_{e=m}^{e=m+n-1} x_e$$

(where m = group number, n = group size, e = integer (epitope) number, x = epitope hydophobicity value).

The methods of the present invention permit the design of candidate polyepitope polypeptides comprising a large number of epitopes of interest (eg 5 to 100 or more) with an increased probability of being efficiently expressed in a suitable host (eg a bacterial host). The epitopes of interest may be a range of epitopes from a single pathogen selected to provide a polyepitope polypeptide that covers the HLA diversity of the target population, or the epitopes of interest may be one or more epitopes from a range of pathogens or tumour antigens. As is evident from the above, one particular application of the methods of the present invention is to the design of candidate polyepitope polypeptides comprising 26 EBV CTL epitopes for use in a vaccine to provide protection against EBV in over 90% of the human population, or for treating diseases associated with EBV such as NPC. Other particular applications of the methods of the present invention relate to the design of candidate polyepitope polypeptides suitable for use in polyepitope vaccines for preventing and/or treating HCV and HIV. Another particular application of the methods of the present invention is to the design of candidate polyepitope polypeptides comprising CTL epitopes from cytomegalovirus (CMV), for use in a vaccine to prevent or treat CMV-causative diseases.

A candidate polypeptide designed in accordance with the methods of the present invention may be expressed by firstly synthesising a polynucleotide encoding the candidate polypeptide according to any of the methods well known to persons skilled in the art, and then by introducing the polynucleotide into a suitable host. Typically, this will be achieved by cloning the polynucleotide into an expression vector and then introducing the expression vector into said host by any of the transformation methods well known to persons skilled in the art. Expression from the expression vector may result in the polypeptide being expressed as a fusion protein comprising the polypeptide and a suitable carrier protein (eg β-galactosidase, glutathione S-transferase or the gp350 structural protein from EBV or a fragment thereof). Alternatively, the polypeptide may be expressed by the host cell, and following isolation of the polypeptide, the polypeptide may be linked to or otherwise associated with a suitable carrier protein. The carrier protein may also confer additional useful properties (ie the carrier protein may comprise useful epitopes or sequences to enhance solubility, further enhance purification procedures, facilitate association with an adjuvant or to which an immune response is desirable).

It is further contemplated that candidate polypeptides designed in accordance with the methods of the present invention may be expressed in prokaryotic expression systems

other than *E. coli*. Typical alternative systems include *B. subtilis*, Salmonella sp., Streptococcus sp., Lactobacillus sp., and Streptomyces sp.

It is also contemplated that candidate polypeptides designed in accordance with the methods of the present invention may be readily expressed in whole cell lysates and non-bacterial host cells as well, and accordingly such alternative expression methods for candidate polypeptides are to be considered as forming part of the present invention. In particular, the present invention is to be considered as extending to a method of expressing a polypeptide in a non-bacterial host cell such as a mammalian cell (eg a CHO cell or COS cell line), a yeast cell (eg *Saccharomyces cerevisiae*) or insect cell (eg SF9 cell line), wherein the method comprises designing a polypeptide in accordance with the method of the first aspect, introducing a polynucleotide encoding the polypeptide into the host cell such that the host cell is capable of expressing the polypeptide, and culturing the host cell under conditions suitable for expression of the polypeptide. The expressed polypeptide may be isolated from the host cell culture by lysing the cells and purifying the polypeptide from the produced cell lysate, or alternatively, the polypeptide could be expressed with a suitable secretion signal such that the polypeptide is secreted into the culture medium (from where it may be purified). Designing a polyepitope polypeptide in accordance with the methods of the present invention may also overcome non-secretion problems which are sometimes experienced when a hydrophobic polypeptide is expressed with a foreign secretion signal.

Where the expressed polypeptide is of pharmacological or veterinary significance, the polypeptide may be formulated into a pharmaceutical or veterinary composition. Generally, such compositions will comprise a pharmaceutically acceptable or veterinary acceptable carrier, and may include other substances and excipients as may be required.

Polyepitope polypeptides may be formulated into vaccine compositions. Generally, such compositions will comprise a pharmaceutically acceptable or veterinary acceptable carrier and may include adjuvants (eg an ISCOM™ adjuvant, DEAE, polysaccharides, saponins, liposomes and virus-like particles), and other substances and excipients as may be required. The vaccine compositions may also include helper epitopes/CD4 epitopes or B-cell epitopes. The vaccine compositions may be adapted for administration to a subject by, for example, intramuscular injection, nasal administration via an aerosol spray, or oral administration. Preferably, the vaccine compositions are ISCOM™ adjuvant compositions.

Polyepitope polypeptides may also be administered to a subject in the form of a viral vaccine (eg a recombinant polyepitope vaccinia or adenovirus) or DNA vaccine.

Thus, in a further aspect, the present invention provides a polynucleotide vaccine comprising a polynucleotide encoding a polypeptide designed in accordance with the method of the first aspect, and a pharmaceutically acceptable carrier and/or adjuvant.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

The term "substantially corresponding" as used herein in relation to an amino acid sequence is intended to encompass the exact amino acid sequence as well as minor variations which do not result in a substantial decrease in the biological activity of the amino acid sequence (eg variations which do not diminish the ability of an epitope to provoke a CTL immune response). These variations may include one or more conservative amino acid substitutions. The conservative amino acid substitutions envisaged are: G, A, V, I, L, M; D, E, N, Q; S, C, T; K, R, H; and P, Nα-alkylamino acids.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is therefore, not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the art relevant to the present invention as it existed in Australia or elsewhere before the filing or priority date of the present specification.

The invention will hereinafter be further described by way of the following non-limiting examples and accompanying figures.

Brief Description of the accompanying Figures:

Figure 1 provides the epitope configuration and amino acid sequences for EBV-polyepitope polypeptides, PT26A and PT26B. Numbers above epitopes represent hydrophobicity values for each epitope calculated with Pinsoft 2 software, specifying an acetyl N-terminal and an amide C-terminal.

Figure 2 provides hydrophobicity plots of PT26A and PT26B. Hydrophobicity values of a moving nine amino acid window are derived using the algorithm of Fauchere and Pliska, 1983.

Figure 3 provides the amino acid sequence of the fusion of residues 21 to 447 of EBV gp350 to PT26A (A) or to PT26B (B).

Figure 4 shows Coomassie stained SDS-PAGE gels showing the time course of expression following induction with IPTG (+IPTG or I) of: (A) PT26A (at approximately 30kDa), (B) gp350/PT26A (at approximately 80kDa), and (C) PT26B expression. Arrows indicate the location of recombinant protein.

Figure 5 provides ELISPOT assay results of CTL responses to the five HLA A2 epitopes contained within the polyepitope polypeptides, PT26A and PT26B, under two formulation conditions: (A) 10μg gp350-PT26A, (B) 10μg gp350-PT26B, and (C) positive control peptide mix containing a mixture of each of the 5 A2 epitopes contained in the polypeptide polypeptide. Each of the epitopes is represented below by their first 3 amino acids. The CTL response of each mouse M1-M5 to each A2 epitope is presented as a bar indicating the number of IFN-γ spots produced.

Figure 6 provides the epitope configuration and amino acid sequences for an EBV polyepitope polypeptide, EBV-NPCa. Numbers above epitopes represent hydrophobicity values for each epitope calculated with Pinsoft 2 software, specifying an acetyl N-terminus and an amide C-terminus.

Figure 7 provides the epitope configuration and amino acid sequences for HIV polyepitope polypeptides, HIVa and HIVb. Numbers above epitopes represent hydrophobicity values for each epitope calculated with Pinsoft 2 software, specifying an acetyl N-terminus and an amide C-terminus. Hydrophobic Index values across 3 epitopes (n = 3) are shown below.

Figure 8 provides the epitope configuration and amino acid sequences for HCV polyepitope polypeptides, HCVa and HCVb. Numbers above epitopes represent hydrophobicity values for each epitope calculated with Pinsoft 2 software, specifying an acetyl N-terminus and an amide C-terminus. Hydrophobic Index values across 3 epitopes (n = 3) are shown below.

Figures 9 and 10 show Coomassie stained SDS-PAGE gels and also immunoblots from an expression time course of constructs HIVa, HIVb, HCVa and HCVb. Figure 9 - Panel A: 1 hour timepoint. Lane 1) Novex SeeBlue+2 MW markers; 2) Negative vector/host control; 3) HIVa uninduced; 4) HIVa induced; 5) HIVb uninduced; 6) HIVb induced; 7) HCVa uninduced; 8) HCVa induced; 9) HCVb uninduced; 10) HCVb induced. Panel B: 2 hour timepoint. Lane 1) Negative vector/host control; 2) Novex SeeBlue+2 MW markers; 3) HIVa uninduced; 4) HIVa induced; 5) HIVb uninduced; 6) HIVb induced; 7) HCVa uninduced; 8) HCVa induced; 9) HCVb uninduced. Figure 10 - Panel A: 3 hour timepoint. Lane 1) Negative vector/host control; 2) HIVa uninduced; 3) HIVa induced; 4)HIVb

uninduced; 5) HIVb induced; 6) Novex SeeBlue+2 MW markers; 7) HCVa uninduced; 8) HCVa induced; 9) HCVb uninduced; 10) HCVb induced. Panel B: Overnight timepoint. Lane 1) Negative vector/host control; 2) HIVa uninduced; 3) HIVa induced; 4)HIVb uninduced; 5) HIVb induced; 6) HCVa uninduced; 7) HCVa induced; 8) HCVb uninduced; 9) HCVb induced; 10) Novex SeeBlue+2 MW markers.

Example 1: EBV polyepitope fusions as vaccine candidates.

MATERIALS AND METHODS

Epitope sequences

The 26 CTL epitopes for inclusion in an EBV vaccine, the proteins from which they originate and HLA type are shown in Table 1.

TABLE 1. CTL epitopes included in the EBV polytopes

HLA Type	EBV Protein	Epitope
A2	LMP2	CLGGLLTMV (SEQ ID NO:6)
	BMLF1	GLCTLVAML (SEQ ID NO:7)
	EBNA6	LLDFVRFMGV (SEQ ID NO:8)
	LMP1	YLLEMLWRL (SEQ ID NO:9)
	LMP1	YLQQNWWTL (SEQ ID NO:10)
A3	EBNA3	RLRAEAQVK (SEQ ID NO:11)
A11	LMP2	SSCSSCPLSKI (SEQ ID NO:12)
A23	LMP2	PYLFWLAAI (SEQ ID NO:13)
A24	LMP2A	TYGPVFMCL (SEQ ID NO:14)
	EBNA4	TYSAGIVQI (SEQ ID NO:15)
B7	EBNA3	RPPIFIRRL (SEQ ID NO:16)
B8	EBNA3	FLRGRAYGL (SEQ ID NO:17)
	EBNA3	QAKWRLQTL (SEQ ID NO:18)
	BZLF1	RAKFKQLL (SEQ ID NO:19)
B27	EBNA4	HRCQAIRKK (SEQ ID NO:20)
	EBNA6	RRIYDLIEL (SEQ ID NO:21)
B35	EBNA4	AVLLHEESM (SEQ ID NO:22)
	EBNA3	YPLHEQHGM (SEQ ID NO:23)
B44	EBNA6	EENLLDFVRF (SEQ ID NO:24)
	EBNA6	EGGVGWRHW (SEQ ID NO:25)
	EBNA4	VEITPYKPTW (SEQ ID NO:26)
B46	EBNA3	VQPPQLTLQV (SEQ ID NO:27)
B57	LMP1	IALYLQQNW (SEQ ID NO:28)
B58	EBNA4	VSFIEFVGW (SEQ ID NO:29)
B60	LMP2	IEDPPFNSL (SEQ ID NO:30)
B62	EBNA4	GQGGSPTAM (SEQ ID NO:31)

Design/Ordering of epitopes

The following method was used to generate ordered arrangements of CTL epitopes to produce a polyepitope sequence with favourable hydrophobicity characteristics:

(i) The hydrophobic value for each epitope was calculated using a suitable algorithm (ie Pinsoft 2 from Mimotopes Pty Ltd, specifying the N-terminus as N-acetyl and the C-terminus as carboxy amide).

(ii) The set of epitopes was ranked in order of decreasing hydrophobicity.

(iii) The rank ordered set of epitopes was divided into 3 equal groups (ie group 1 = most hydrophobic, group 2 = middle hydrophobicity and group 3 = least hydrophobic (most hydrophilic)). Residual epitopes (ie 2 epitopes left over after the set of 26 was divided by 3), were included in the most hydrophilic group.

(iv) Triplets of epitopes were created by taking the most hydrophilic of group 2 (ie last in group 2), then the most hydrophobic epitope (ie number 1 in group 1) and lastly the most hydrophilic (ie last in group 3). This was continued until all epitopes in groups 1 and 2 had been used (nb "Leftover" epitopes were added to the C-terminal end of the final sequence arrangement).

(v) The triplets were then arranged into a sequence in the order in which they were produced (ie Triplet 1 - Triplet 2 – Triplet 3 – etc).

(vi) The hydrophobicity of this triplet arrangement was then plotted using a suitable algorithm (ie Fauschere and Pliska).

(vii) If and where necessary, relocating triplets from areas of low hydrophobicity into areas of high peak hydrophobicity in order to reduce hydrophobic amplitude.

(viii) Re-calculating the hydrophobicity plots and continuing, if necessary, to shuffle triplets as in the step (vii) above.

(ix) Any residual epitopes (ie least hydrophilic of group 3) can be placed C-terminally in the final sequence arrangement or can be used to further reduce local peaks in hydrophobicity by inserting them adjacent to epitopes of peak hydrophobicity, according to a hydrophobicity plot of the assembled triplets.

(x) Any affinity tags (usually hydrophilic, eg a hexa-histidine sequence) should be located either N- or C- terminally or preferably C-terminally if the construct is a fusion protein.

(xi) Confirmation of satisfactory HI.

Using this process, EBV polyepitope configurations PT26A and PT26B were created. The example of PT26A is shown in Table 4.

Hydrophobic Index (HI) calculations

HI values for favourable configurations (PT26A, PT26B) were calculated according to the mathematical expression:-

$$HI_m = \sum_{e=m}^{e=m+n-1} x_e$$

(where m = group number, n = group size, e = integer (epitope) number, x = epitope hydophobicity value) over values of n from 2 to 5.

Preparation of recombinant proteins

DNA sequences encoding the polyepitopes (PT26A and PT26B) were generated from synthetic oligonucleotides using a Splicing by Overlap Extension technique (SOE) as described by Horton et al (1995). The codon usage was optimised for *E. coli* expression (Wada et al 1992). The polyepitopes were tagged at the C-terminus with a hexa-histidine tag for protein purification and detection. The DNA was subcloned into pET28b (Novagen) and transformed into *E. coli* BL21(DE3) cells (Novagen) for expression.

A fragment corresponding to the N-terminal region (amino acid residues 21 – 447) of EBV gp350 was amplified from plasmid DNA containing the full length gp350 sequence by PCR using the following oligonucleotides:

5' AGGGATCCCATGGAAGATCCTGGTTTTTTC 3' (forward) (SEQ ID NO:32) and

5' TCTAGAGGTCGACACCTGTCGTTGTATTGGG 3' (reverse) (SEQ ID NO:33). This DNA fragment was subcloned into pET28b (Novagen) containing the polyepitope insert, resulting in an in-frame fusion between gp350 and the polyepitope polypeptide. The constructs were referred to as gp350/PT26A (Figure 3A) and gp350/PT26B (Figure 3B).

For protein expression testing, transformed cells were grown in 50mg/ml Kanamycin containing L broth at 37°C until OD600 reached 2. Protein expression was induced by the addition of IPTG (0.25mM) and cells were grown for another 3 hours. Cells were pelleted and boiled in SDS sample buffer before analysing by SDS-PAGE.

For protein purification, cells induced by IPTG were pelleted, resuspended in binding buffer (20mM Tris-HCl pH 7.9, 0.5M NaCl, 5mM imidazole) and then sonicated. Inclusion bodies were pelleted and washed in buffer. The proteins were solubilised overnight in binding buffer containing 8M urea and purified on a Ni^{++}-NTA column.

Preparation of ISCOM™ formulations

ISCOMATRIX™-adjuvant was prepared by combining adjuvant components in a formulation vessel. Cholesterol, 1,2, dipalmitoyl phosphatidylcholine (DPPC), and ISCOPREP™ as a source of purified Quillaja saponins, were mixed in a weight ratio of 1:1:5 in the presence of the detergent Mega-10 (United States Patent No. 5,679,354) at a concentration of 2%. The detergent was removed by diafiltration with PBS and the formation of ISCOMATRIX™ confirmed by negative contrast electron microscopy revealing complexes including cage-like structures typically with a diameter of 40nm. ISCOM™-adjuvanted vaccines were prepared by mixing the EBV polyepitope antigen with preformed ISCOMATRIX™-adjuvant, which was prepared as described below: The dose strength of ISCOM-adjuvant as saponin was quantified by reverse phase HPLC assay.

ISCOM™ vaccines were prepared by gentle mixing at 22°C of an equal volume of 2x final dose strength ISCOMATRIX™ with an equal volume of 2x final dose strength EBV polyepitope antigen (gp350-PT26A and B). After 60 minutes, the formulation was subjected to extensive dialysis, in order to remove urea, at 4°C into PBS buffer pH6.2 using 12,000 molecular weight cut off dialysis membrane (Cellu Sep T3, San Antonio Texas).

Mouse immunogenicity

Dosing

Female HLA A2 transgenic C57Bl/6 mice (HDD) were bred at Queensland Institute of Medical Research (QIMR, Brisbane, Australia) and immunised at 5-7 weeks of age. Mice were housed in filter-topped cages in the PC3 animal facility at QIMR. Groups of 4 or 5 mice were dosed sub-cutaneously at the tail base with 0.1ml formulation. This was followed by removal of spleens at day 21 for *ex-vivo* ELISPOT assay (below).

Mice dosed sub-cutaneously, received 10μg ISCOM™-adjuvant (as saponin) and 10μg EBV polyepitope antigen. For a vaccine control group, mice were dosed sub-cutaneously with a peptide mixture comprising free peptides (Mimotopes Pty Ltd) formulated with tetanus toxoid and Montanide ISA 720 (SEPPIC, Paris, France) as previously described (Elliot et al, 1999). Peptide control immunisations come from two groups of mice, one group immunised with GLCTLVAML(SEQ ID NO:6)/YLLEMLWRL(SEQ ID NO:9)/LLDFVRFMGV(SEQ ID NO:8) peptide mixture and the other YLQ/CLG. A mixture of all five epitopes showed some insolubility problems.

CTL activity (ex-vivo ELISPOT)

Ex vivo ELISPOT measures/quantitates both effector and memory CTL which secrete IFNγ. Peptide-specific IFNγ secreting cells are enumerated by an enzyme linked immuno-spot (ELISpot) assay modified from Murali-Krishna *et al.* Flat bottomed 96-well microtitre plates are coated overnight with 5 ug/mL of rat anti-mouse IFNγ antibody(clone RA-6A2, BD PharMingen, San Diego, California, USA). Coated plates are then blocked for 1 hour with 1% FBS in PBS, and then washed three times with PBS/0.05% Tween 20 (PBS-T), and incubated for 1 hour at 37°C with medium comprising RPMI 1640, supplemented with 100 μg/ml streptomycin and 100 IU/ml penicillin, 10% FBS and 10^{-5} M 2-mercaptoethanol. Mouse splenocytes were then treated with red blood cell lysis buffer, washed and resuspended to 1 x 10^7 cells/ml in medium, for use in the *ex vivo* IFNγ ELISPOT assay. Splenocytes (1 x 10^6/well) are then placed in the first wells of the ELISpot plate and serially diluted two fold. Recombinant human IL-2 (kindly provided by Cetus Corp., Emeryville, California, USA) is then added to the plate at a final concentration of 5 IU/well together with EBV peptide (Mimotopes Pty Ltd) at a final concentration of 100 μg/ml. Media containing IL-2 without peptide is added to control wells. The final volume in each well is 100 μl. Plates are incubated at 37°C in 5% CO_2 for approximately 18 hours. After incubation, cells are lysed by rinsing the plates in H_2O and then washed twice in PBS-T. Biotinylated anti-mouse IFNγ antibody clone XMG1.2 (BD Phar Mingen) is diluted 1:500

(2 μg/ml final concentration) in PBS-T/5% FBS and added to all wells at 50 μl/well and incubated for 2 hours at RT. Plates are then washed in PBS-T and streptavidin-alkaline phosphatase, diluted 1:400 in PBS-T/5% FBS, is added at 50 μl per well and incubated for a further 2 hours. After washing, plates are developed by adding Sigma Fast BCIP/NBT substrate at 50 ul/well. Plates are incubated at 37°C for approximately 20 minutes to allow colour development, and then washed with water to stop the reaction. IFNγ specific spots are counted using KS ELISPOT Reader (Zeiss).

RESULTS

Epitope Fusions

26 EBV CTL epitopes were selected to provide >90% human population coverage for a vaccine formulation.

In order to link these CTL epitopes (Table 1) together and facilitate the design of a polyepitope antigen to form the basis of an EBV prophylactic vaccine, the hydrophobicity value of each epitope was calculated using Pinsoft 2 software (Table 2). Two versions of 26 epitopes were then ordered into configurations PT26A and PT26B (Figure 1), which reduced peak hydrophobicity and hydrophobic sequence length (Figure 2). When these constructs were cloned for expression in *E. coli* it was found that only one of the configurations (PT26A) was able to produce a polyepitope polypeptide (Figure 4A). PT26B was not produced (Figure 4C).

To identify a potential reason for this unexpected finding, local areas of high hydrophobicity were examined by summation of overlapping hydrophobicity values (Pinsoft 2, Mimotopes Pty Ltd) to provide a hydrophobicity index (HI) over varying numbers of peptides in a group (n). For n=2, no correlation was apparent. However, for n=3 and n=4 (Table 3), the highest HI values for the expressed sequence (PT26A) were lower (1.79 and 2.51 respectively) than the highest values obtained for the non-expressed sequence (2.02 and 2.54 respectively). For n=5, again no significant differences were seen. This would indicate that there were local areas of slightly higher hydrophobicity in PT26B than PT26A.

The above analysis can be represented by the mathematical expression:-

$$HI_m = \sum_{e=m}^{e=m+n-1} x_e$$

(where m = group number, n = group size, e = integer (epitope) number, x = epitope hydophobicity value).

Overall, the results with n=3 and n=4 appeared to show the most distinctive differences. This would make the prediction that to be able to express linked, random, short amino acid sequences in *E. coli* in SDS-PAGE detectable amounts, the hydrophobic index over groups of three epitope sequences would preferably need to be less than 1.8 ($HI_3 < 1.8$) and/or that over groups of four the hydrophobic index would preferably need to be less than 2.5 ($HI_4 < 2.5$), where x was calculated using Pinsoft 2 (Mimotopes Pty Ltd) and specifying the N-terminus as N-acetyl and the C-terminus as carboxy amide. Different cut-off values will be obtained with different hydrophobicity algorithms.

Table 4 shows the HI values over 3 peptides (n=3) for 15 random arrangements of the 26 EBV CTL epitopes that were generated and analysed by calculating the HI. This shows that all 15 random configurations contain multiple HI values which are all in the range predicted to preclude the production of a recombinant polypeptide in *E. coli* (ie HI greater than 1.8). This also shows that the arrangements made in accordance with the present methods are unlikely to be arrived at without application of the insights embodied in the present invention.

TABLE 2: Ordering process for generation of a polyepitope polypeptide for 26* EBV CTL epitopes (PT26A).

The hydrophobicity value for each epitope is calculated, then the epitopes are rank ordered, and grouped into triplets. The sequence is assessed using a hydrophobicity plot and scored for HI value by summing the epitope hydrophobicity values over a moving 3-mer window. If necessary, fine-tuning of the epitope order is done and the sequence reassessed. The final epitope order and amino acid sequence for the 26* EBV CTL epitopes and hexa-histidine affinity tag is shown below.

HLA Type	EPITOPE	Hydropho-bicity (Hyd) (Pinsoft 2)	Rank ordered on Hyd	Hyd	Grouped into triplets	Hyd.	Order after fine tuning	Hyd	Sum Hyd for triplets
A2	CLGGLLTMV	0.82	PYLFWLAAI	1.02	*FLRGRAYGL*	*0.38*	*FLRGRAYGL*	*0.38*	
A2	GLCTLVAML	0.85	GLCTLVAML	0.85	PYLFWLAAI	1.02	PYLFWLAAI	1.02	
A2	LLDFVRFMGV	0.71	YLLEMLWRL	0.85	HRCQAIRKK	-0.07	HRCQAIRKK	-0.07	1.33
A2	YLLEMLWRL	0.85	IALYLQQNWWTL*	0.83	*RRIYDLIEL*	*0.39*	*RRIYDLIEL*	*0.39*	1.34
A2/B57	IALYLQQNWWTL* (SEQ ID NO:34)	0.83	TYGPVFMCL	0.83	GLCTLVAML	0.85	*VQPPQLTLQV*	*0.55*	0.87
A3	RLRAEAQVK	-0.06	VSFIEFVGW	0.83	RLRAEAQVK	-0.06	GLCTLVAML	0.85	1.79
A11	SSCSSCPLSKI	0.45	CLGGLLTMV	0.82	*IEDPPFNSL*	*0.40*	RLRAEAQVK	-0.06	1.34
A23	PYLFWLAAI	1.02	LLDFVRFMGV	0.71	YLLEMLWRL	0.85	*IEDPPFNSL*	*0.40*	1.19
A24	TYSAGIVQI	0.53	*VQPPQLTLQV*	*0.55*	GQGGSPTAM	0.18	YLLEMLWRL	0.85	1.19
A24	TYGPVFMCL	0.83	*TYSAGIVQI*	*0.53*	*AVLLHEESM*	*0.43*	GQGGSPTAM	0.18	1.43

TABLE 2 continued

B7	RPPIFIRRL	0.47	*VEITPYKPTW*	*0.52*	IALYLQQNWWTL*	0.83	AVLLHEESM	0.4 identifying 3	1.46
B8	FLRGRAYGL	0.38	*RPPIFIRRL*	*0.47*	RAKFKQLL	0.20	IALYLQQNWWTL*	0.83	1.44
B8	QAKWRLQTL	0.32	*SSCSSCPLSKI*	*0.45*	*SSCSSCPLSKI*	*0.45*	RAKFKQLL	0.20	1.46
B8	RAKFKQLL	0.20	*AVLLHEESM*	*0.43*	TYGPVFMCL	0.83	*SSCSSCPLSKI*	*0.45*	1.48
B27	HRCQAIRKK	-0.07	*IEDPPFNSL*	*0.40*	QAKWRLQTL	0.32	TYGPVFMCL	0.83	1.48
B27	RRIYDLIEL	0.39	*RRIYDLIEL*	*0.39*	*RPPIFIRRL*	*0.47*	QAKWRLQTL	0.32	1.60
B35	YPLHEQHGM	0.34	*FLRGRAYGL*	*0.38*	VSFIEFVGW	0.83	RPPIFIRRL	*0.47*	1.62
B35	AVLLHEESM	0.43	EGGVGWRHW	0.36	YPLHEQHGM	0.34	VSFIEFVGW	0.83	1.62
B44	VEITPYKPTW	0.52	EENLLDFVRF	0.35	*VEITPYKPTW*	*0.52*	YPLHEQHGM	0.34	1.64
B44	EGGVGWRHW	0.36	YPLHEQHGM	0.34	CLGGLLTMV	0.82	*VEITPYKPTW*	*0.52*	1.69
B44	EENLLDFVRF	0.35	QAKWRLQTL	0.32	EENLLDFVRF	0.35	CLGGLLTMV	0.82	1.68
B46	VQPPQLTLQV	0.55	RAKFKQLL	0.20	*TYSAGIVQI*	*0.53*	EENLLDFVRF	0.35	1.69
B58	VSFIEFVGW	0.83	GQGGSPTAM	0.18	LLDFVRFMGV	0.71	*TYSAGIVQI*	*0.53*	1.70
B60	IEDPPFNSL	0.40	RLRAEAQVK	-0.06	EGGVGWRHW	0.36	LLDFVRFMGV	0.71	1.59
B62	GQGGSPTAM	0.18	HRCQAIRKK	-0.07	*VQPPQLTLQV*	*0.55*	EGGVGWRHW	0.36	1.60
	HHHHHH (SEQ ID NO:35)	0.04	HHHHHH	0.04	HHHHHH	0.04	HHHHHH	0.04	1.11

(* The epitope IALYLQQNWWTL is comprised of two overlapping CTL epitopes IALYLQQNW and YLQQNWWTL that were combined for this study.)

TABLE 3:

3mers	(n=3)																						
PT26A	1.33	1.34	0.87	1.79	1.34	1.19	1.19	1.43	1.46	1.44	1.46	1.48	1.48	1.6	1.62	1.62	1.64	1.69	1.68	1.69	1.7	1.59	1.6
PT26B	1.33	1.34	1.17	1.18	1.19	0.87	1.64	1.6	1.9	1.39	1.48	1.48	1.6	1.62	1.62	1.64	1.69	1.68	1.69	2.02	1.38	1.46	1.16
4mers	(n=4)																						
PT26A	1.72	1.89	1.72	1.73	1.74	2.04	1.37	1.86	2.29	1.64	1.91	2.31	1.8	2.07	2.45	1.96	2.16	2.51	2.03	2.22	2.41	1.95	
PT26B	1.72	2.19	1.11	1.58	1.72	1.58	2	2.43	2.1	1.84	2.31	1.8	2.07	2.45	1.96	2.16	2.51	2.03	2.54	2.2	1.81	2.01	

Hydrophobic Index **TABLE 4:**

3mers (n=3)																								# >1.8
PT26B	1.33	1.34	1.17	1.18	1.19	0.87	1.64	1.6	1.9	1.39	1.48	1.48	1.6	1.62	1.62	1.64	1.69	1.68	1.69	2.02	1.38	1.46	1.16	2
PT26A	1.33	1.34	0.87	1.79	1.34	1.19	1.19	1.43	1.46	1.44	1.46	1.48	1.48	1.6	1.62	1.62	1.64	1.69	1.68	1.69	1.7	1.59	1.6	0
Random																								
1	1.93	1.62	1.41	0.93	1	1.67	1.66	1.64	0.72	0.91	0.82	1.21	1.51	1.09	1.29	0.89	1.5	2	2.42	2.25	2.05	2.03	1.85	7
2	0.69	0.64	1.54	1.65	1.75	1.31	1.39	0.88	1.51	1.81	2.58	2.41	1.94	1.75	1.24	1.69	1.49	1.98	1.58	1.44	0.81	0.91	1.55	5
3	1.67	1.47	1.62	2	1.52	1.1	0.45	0.96	1.58	1.8	1.33	1.61	1.74	1.88	1.9	1.8	1.67	0.76	0.8	1.24	1.62	1.86	1.39	5
4	1.86	1.5	1.71	1.28	1.36	1.19	1.17	1.56	2.05	2.52	2.15	2.13	1.21	1.78	1.15	1.69	0.85	0.59	0.51	1.16	1.56	1.69	1.41	5
5	1.67	1.36	1.44	1.88	1.68	1.58	0.93	0.99	0.49	0.51	0.98	1.88	2.08	2.25	2.13	2.2	1.53	0.76	1.11	1.61	2.03	1.55	1.25	7
6	1.1	0.94	1.39	1.46	2.11	1.46	1.58	1.22	1.47	1.74	1.62	2.02	1.91	2.58	2.05	1.87	1.23	1.74	1.73	1.28	1.28	1.15	1.15	6
7	1.03	0.58	0.72	1.34	1.6	1.22	0.85	1.05	0.94	1.14	1.06	1.22	1.27	1.78	2.11	2.02	2.21	1.71	2.2	1.63	1.81	1.8	2.18	7
8	1.48	1.88	1.52	2.03	1.7	1.41	1.25	0.66	0.82	0.65	1.74	1.75	1.31	0.68	1.16	1.65	1.79	1.78	2.18	1.97	1.51	1.53	1.61	4
9	2.04	1.83	1.75	1.16	1.02	1.45	1.85	2	2.01	1.56	1.74	1.74	1.76	1.17	1.19	1.15	1.53	1.39	0.96	0.82	0.56	1.48	1.82	6
10	1.24	1.15	0.71	1.62	1.69	2.13	1.68	1.57	1.29	1.24	1.72	2.02	1.85	1.74	1.42	2.26	1.91	1.81	1.11	1.58	1.35	1.55	0.65	6
11	0.52	0.94	0.86	1.03	1.1	1.23	1.26	1.66	2.06	1.88	1.52	1.5	1.82	2.18	2.37	2.38	1.48	0.85	1.17	1.95	1.9	1.6	1.71	8
12	1.56	1.86	1.97	1.46	1.45	1.4	2.05	1.16	0.72	0.26	0.88	1.96	1.92	1.77	1.58	2.06	2.02	1.53	0.88	0.99	1.5	1.84	1.82	9
13	0.68	0.74	1.36	1.83	1.72	1.57	0.92	1.4	1.35	1.7	1.35	1.32	1.64	2	2.51	2.37	2.39	2.08	1.31	1.48	1.16	1.6	1.01	6
14	1.4	1.35	1.36	1.17	1.62	2.06	1.62	1.24	1.39	1.2	0.91	0.7	0.84	1.18	1.41	1.92	2.23	2.51	2.09	1.62	1.14	1.53	1.88	6
15	0.52	1.03	1.67	2	2.02	1.85	1.67	1.63	1.61	1.66	1.55	1.27	1.7	1.77	1.74	1.25	0.79	1.09	1.58	2.5	1.86	1.74	1.25	5

Fusions of these polyepitopes with the N-terminal 400 amino acids of a naturally-occurring EBV protein (gp350).

Provision of CD4 help has previously been shown to improve CTL induction (Thuy et al, 2001) and the EBV structural protein gp350 was identified as the preferred candidate to provide this property because it would provide cognate help. Hence the two polyepitopes, PT26A and PT26B, the latter of which was unable to be expressed in *E. coli*, were cloned onto the C-terminus of the N-terminal 400 amino acids of gp350 (Figure 3) and expressed as the fusion protein in *E. coli*. Both of these fused polypeptides were well-produced, being clearly visible on a Coomassie-stained gel above the background of *E. coli* proteins (profile for PT26A shown in Figure 4B).

CTL activity

Vaccination of HLA A2 transgenic mice with either gp350-PT26A-ISCOM™ vaccine or gp350-PT26B-ISCOM™ vaccine induced a CTL immune response (IFN ELISPOT) to all five A2 epitopes (Figure 5), thus indicating that all A2 epitopes were properly processed and presented to the immune system.

Example 2: EBV polyepitope fusions as nasopharyngeal carcinoma vaccine candidates.

MATERIALS AND METHODS

Epitope sequences

The 20 CTL epitopes for inclusion in an EBV-NPC vaccine, the proteins from which they originate and HLA type are shown in Table 5.

Design/Ordering of epitopes

An ordered arrangement of CTL epitopes to produce a polyepitope sequence with favourable hydrophobicity characteristics was generated by the method described in Example 1 (i) – (xi).

The final shuffle involved taking YPLHEQHGM (SEQ ID NO:23) from position 3 and changing with CLGGLLTMV (SEQ ID NO:16) at position 19 to reduce a high hydrophobic index (HI) which resulted from summing epitopes 18, 19 and 20.

The ordering process for this optimised EBV-NPC polyepitope (EBV-NPCa) configuration is shown in Table 6.

Hydrophobic Index (HI) calculations

HI values for EBV-NCPa were calculated according to the mathematical expression:-

$$HI_m = \sum_{e=m}^{e=m+n-1} x_e$$

(where m = group number, n = group size, e = integer (epitope) number, x = epitope hydophobicity value) over values of n from 2 to 5).

Generation of DNA constructs

The amino acid sequence of the EBV-NPC polyepitope was back translated to DNA using the Dnastar Editseq software (DNASTAR Inc, Madison, Wisconsin, USA) and codons optimised for *E. coli* expression. A C-terminal hexa-histidine tag was incorporated for purification and detection. The DNA encoding the polyepitope was generated from synthetic oligonucleotides using a Splicing by Overlap Extension technique (SOE) as described by Horton et al (1995). This was cloned into pET24b (Novagen) and the resulting construct sequenced to ensure that no errors were present (Big Dye Terminator Kit V3.1; Applied Biosystems). For expression purposes, DNA was transformed into *E. coli* BL21(DE3) cells (Novagen).

Protein Expression and Analysis

Tranformed cells were grown at 37°C in Terrific Broth containing 50mg/ml Kanamycin. At an OD600 of ~2, protein expression was induced by addition of 0.5mM IPTG and samples taken at 1 hour ,2 hours, 3 hours and overnight post-induction. Cells were pelleted, resuspended to equal densities and boiled in SDS sample buffer prior to analysing by SDS-PAGE on Novex 4-20% Tris-Glycine gels. Gels were analysed both by Coomassie Blue staining and immunoblotting. Blots were probed with Dianova anti hexa-histidine monoclonal antibody.

TABLE 5: CTL epitopes included in the EBV-NPCa polyepitope

HLA Type	EBV Protein	Epitope
A11	LMP2	SSCSSCPLSKI (SEQ ID NO:12)
A23, A24	LMP2	PYLFWLAAI (SEQ ID NO:13)
A24	LMP2	TYGPVFMCL (SEQ ID NO:14)
A25	LMP2	VMSNTLLSAW (SEQ ID NO:36)
A2.1	LMP2	CLGGLLTMV (SEQ ID NO:6)
A2.3	LMP2	LLSAWILTA (SEQ ID NO:37)
A2.6	LMP2	LTAGFLIFL (SEQ ID NO:38)
B8	LMP2	CPLSKILL (SEQ ID NO:39)
B27	LMP2	RRRWRRLTV (SEQ ID NO:40)
B40	LMP2	IEDPPFNSL (SEQ ID NO:30)
A2, A68, A69	LMP1	YLLEMLWRL (SEQ ID NO:9)
A2	LMP1	YLQQNWWTL (SEQ ID NO:10)
A2	LMP1	ALLVLYSFA(SEQ ID NO:41)
B57, B58	LMP1	IALYLQQNW (SEQ ID NO:28)
A3	EBNA3	RLRAEAQVK (SEQ ID NO:11)
B8	EBNA3	QAKWRLQTL (SEQ ID NO:18)
B35	EBNA3	YPLHEQHGM (SEQ ID NO:23)
B27	EBNA4	HRCQAIRKK (SEQ ID NO:20)
B62	EBNA4	GQGGSPTAM (SEQ ID NO:31)
B8	BZLF1	RAKFKQLL (SEQ ID NO:19)

TABLE 6: Ordering process for generation of a polypepitope polypeptide for 20 EBV CTL epitopes (EBV-NPCa)

The hydrophobicity value for each epitope is calculated, then the epitopes are rank ordered, and grouped into triplets. The sequence is assessed using a hydrophobicity plot and scored for HI value by summing the epitope hydrophobicity values over a moving 3-mer window. If necessary, fine-tuning of the epitope order is done and the sequence is reassessed. The final epitope order and amino acid sequence for the 20 EBV CTL epitopes and C-terminal hexa-histidine affinity tag is shown below.

Bold font; most hydrophobic epitopes of the set used as the first epitope in each triplet.

Italic font; most hydrophilic epitopes of the set used as the second epitope in each triplet.

Normal font; epitopes of set with mid-hydrophobicity used as the third epitope within each triplet.

HLA Type	EPITOPE	Hydrophobicity (Hyd) (Pinsoft 2)	Rank ordered on Hyd and divided into 3 groups	Hyd	Optimised sequence grouped into triplets	Hyd	Sum Hyd for triplets [HI, n=3]	Order after fine tuning (epitopes 3 & 19 swapped)	Hyd	Sum Hyd for triplets [HI, n=3]
A23, A24	PYLFWLAAI	0.45	SSCSSCPLSKI	1.02	**SSCSSCPLSKI**	1.02		**SCSSCPLSKI**	1.02	
A11	SSCSSCPLSKI	1.02	LTAGFLIFL	0.98	*HRCQAIRKK*	-0.07		*HRCQAIRKK*	-0.07	
A24	TYGPVFMCL	0.83	LLSAWILTA	0.88	YPLHEQHGM	0.34	1.29	CLGGLLTMV	0.82	1.77
B27	RRRWRRLTV	0.01	YLLEMLWRL	0.85	**LTAGFLIFL**	0.98	1.25	**LTAGFLIFL**	0.98	1.73
A2.3	LLSAWILTA	0.88	ALLVLYSFA	0.85	*RLRAEAQVK*	-0.06	1.26	*RLRAEAQVK*	-0.06	1.74
A2.6	LTAGFLIFL	0.98	TYGPVFMCL	0.83	**IEDPPFNSL**	0.4	1.32	**IEDPPFNSL**	0.4	1.32
A2.1	CLGGLLTMV	0.82	CLGGLLTMV	0.82	**LLSAWILTA**	0.88	1.22	**LLSAWILTA**	0.88	1.22
A25	VMSNTLLSAW	0.64	CPLSKILL	0.78	*RRRWRRLTV*	0.01	1.29	*RRRWRRLTV*	0.01	1.29

TABLE 6 continued

B40	IEDPPFNSL	0.4	YLQQNWWTL	0.71	PYLFWLAAI	0.45	1.34	PYLFWLAAI	0.45	1.34
A2, A68, A69	YLLEMLWRL	0.85	IALYLQQNW	0.67	YLLEMLWRL	0.85	1.31	YLLEMLWRL	0.85	1.31
A2	YLQQNWWTL	0.71	VMSNTLLSAW	0.64	*GQGGSPTAM*	0.18	1.48	*GQGGSPTAM*	0.18	1.48
A2	ALLVLYSFA	0.85	PYLFWLAAI	0.45	VMSNTLLSAW	0.64	1.67	VMSNTLLSAW	0.64	1.67
B57, B58	IALYLQQNW	0.67	IEDPPFNSL	0.4	ALLVLYSFA	0.85	1.67	ALLVLYSFA	0.85	1.67
B8	CPLSKILL	0.78	YPLHEQHGM	0.34	*RAKFKQLL*	0.20	1.69	*RAKFKQLL*	0.20	1.69
B35	YPLHEQHGM	0.34	*QAKWRLQTL*	0.32	IALYLQQNW	0.67	1.72	IALYLQQNW	0.67	1.72
B8	QAKWRLQTL	0.32	*RAKFKQLL*	0.20	TYGPVFMCL	0.83	1.7	TYGPVFMCL	0.83	1.70
B8	RAKFKQLL	0.20	*GQGGSPTAM*	0.18	*QAKWRLQTL*	0.32	1.82	*QAKWRLQTL*	0.32	1.82
B62	GQGGSPTAM	0.18	*RRRWRRLTV*	0.01	YLQQNWWTL	0.71	1.86	YLQQNWWTL	0.71	1.86
A3	RLRAEAQVK	-0.06	*RLRAEAQVK*	-0.06	CLGGLLTMV	0.82	1.85	YPLHEQHGM	0.34	1.37
B27	HRCQAIRKK	-0.07	*HRCQAIRKK*	-0.07	CPLSKILL	0.78	2.31	CPLSKILL	0.78	1.83
			HHHHHH	0.04	HHHHHH	0.04	1.16	HHHHHH	0.04	1.16

Example 3: HIV polyepitope fusions as vaccine candidates.

MATERIALS AND METHODS

Epitope sequences

The 26 CTL epitopes for inclusion in a HIV vaccine, the proteins from which they originate and HLA type are shown in Table 7.

Design/Ordering of epitopes

An ordered arrangement of CTL epitopes to produce a polyepitope sequence with favourable hydrophobicity characteristics was generated by the method described in Example1 (i) – (xi). At the same time, five random sequences were generated and one of these (HIVb) was taken for comparison with the optimised sequence.

The ordering process for the optimised HIV polyepitope (HIVa) configuration is shown in Table 8.

Hydrophobic Index (HI) calculations

HI values for both configurations (HIVa and HIVb) were calculated according to the mathematical expression:-

$$HI_m = \sum_{e=m}^{e=m+n-1} x_e$$

(where m = group number, n = group size, e = integer (epitope) number, x = epitope hydophobicity value) over values of n from 2 to 5).

Generation of DNA constructs

Each polyepitope amino acid sequence was back translated to DNA using the Dnastar Editseq software and codons optimised for *E. coli* expression. C-terminal hexa-histidine tags were incorporated for purification and detection. The DNA encoding the polyepitopes was generated from synthetic oligonucleotides using a Splicing by Overlap Extension technique (SOE) as described by Horton et al (1995). These were cloned into pET24b (Novagen) and the resulting constructs sequenced to ensure that no errors were present (Big Dye Terminator Kit V3.1; Applied Biosystems). For expression purposes, DNA was transformed into *E. coli* BL21(DE3) cells (Novagen).

Protein Expression and Analysis

Tranformed cells were grown at 37°C in Terrific Broth containing 50mg/ml Kanamycin. At an OD600 of ~2, protein expression was induced by addition of 0.5mM IPTG and samples taken at 1 hour, 2 hours, 3hours and overnight post-induction. Cells were pelleted, resuspended to equal densities and boiled in SDS sample buffer prior to analysing by SDS-PAGE on Novex 4-20% Tris-Glycine gels. Gels were analysed both by Coomassie Blue staining and immunoblotting. Blots were probed with Dianova anti hexa-histidine monoclonal antibody.

RESULTS

Epitope fusions

26 HIV CTL epitopes were selected to provide the components of a vaccine formulation. In order to link these CTL epitopes (Table 5) together and facilitate the design of a polyepitope antigen to form the basis of a HIV vaccine, the hydrophobicity value of each epitope was calculated (as in the case of Example 1) using Pinsoft 2 software. Two versions of the 26 epitopes were then created (Figure 7), one which reduced peak hydrophobicity and hydrophobic sequence length (HIVa) and another in which the epitopes were randomly arranged (HIVb). These constructs were then assembled and cloned into *E.coli* for a comparison of their ability to produce a polyepitope polypeptide.

HIVa (optimised polyepitope)

Good expression of polyepitope polypeptide at the predicted MW of 29kDa was observed on Coomassie stained gels from the 1 hour time point and the protein was recognised by an anti hexa-histidine monoclonal antibody on the immunoblot (Figures 9 and 10). Maximum expression was reached by 1 hour post-induction. Leaky, uninduced expression was seen at each time point, gradually increasing to induced levels after overnight incubation. A potential dimer was visible only by immunoblot after overnight induction, with some higher molecular weight material also being detected at 3 hours and overnight post-induction timepoints.

HIVb (random polyepitope)

No polyepitope polypeptide was detected on the stained gel or by immunoblotting (Figures 9 & 10).

DISCUSSION

Use of the above algorithm to order the 26 CTL epitopes has allowed the expression of an HIV polyepitope polypeptide in good yields. On the other hand, expression of a polyepitope sequence which was randomly ordered failed to yield any detectable product.

TABLE 7: CTL epitopes included in the HIV polytopes

HLA Type	HIV Protein	Epitope
A3	p17	RLRPGGKKK (SEQ ID NO: 42)
A*2402,A24,A23	p17	KYKLKHIVW (SEQ ID NO: 43)
B35	p17	WASRELERF (SEQ ID NO: 44)
B7,B8	p17	RPGGKKKYKL (SEQ ID NO: 45)
A2,A*0202,B62	p17	SLYNTVATL (SEQ ID NO: 46)
B8,B60	p17	EIKDTKEAL (SEQ ID NO: 47)
A2,A*0202	p24	TLNAWVKVV (SEQ ID NO: 48)
B7,B42,B53	p24	TPQDLNTML (SEQ ID NO: 49)
A2	p24	MTNNPPIPV (SEQ ID NO: 50)
B27	p24	KRWIILGLNK (SEQ ID NO: 51)
A28, A74	Protease	VTLWQRPLV (SEQ ID NO: 52)
A2, A*0201	Protease	LVGPTPVNI (SEQ ID NO: 53)
A2,A0201	Reverse Transcriptase	ALVEICTEM (SEQ ID NO: 54)
A2,B51	Reverse Transcriptase	YTAFTIPSI (SEQ ID NO: 55)
A3,A11	Reverse Transcriptase	AIFQSSMTK (SEQ ID NO: 56)
A2,A*0201	Reverse Transcriptase	VIYQYMDDL (SEQ ID NO: 57)
A2,B60	Reverse Transcriptase	KIEELRQHL (SEQ ID NO: 58)
A2	Reverse Transcriptase	ILKEPVHGV (SEQ ID NO: 59)
A11	Reverse Transcriptase	IYQEPFKNLK (SEQ ID NO: 60)
B44	Reverse Transcriptase	TWETWWTEYW (SEQ ID NO: 61)
A2	Reverse Transcriptase	PLVKLWYQL (SEQ ID NO: 62)
B7,A3	Reverse Transcriptase	YLAWVPAHK (SEQ ID NO: 63)
A2,A*0201	Integrase	LLWKGEGAV (SEQ ID NO: 64)
A2,A*0201	Vpr	AIIRILQQL (SEQ ID NO: 65)
B7	Vpu	IPIVAIVALV (SEQ ID NO: 66)
A2,A2.1	gp160	KLWVTVYYGV (SEQ ID NO: 67)

TABLE 8: Ordering process for generation of a polypepitope polypeptide for 26 HIV CTL epitopes (HIVa).

The hydrophobicity value for each epitope is calculated, then the epitopes are rank ordered, and grouped into triplets. The sequence is assessed using a hydrophobicity plot and scored for HI value by summing the epitope hydrophobicity values over a moving 3-mer window. If necessary, fine-tuning of the epitope order is done and the sequence is reassessed. The final epitope order and amino acid sequence for the 20 EBV CTL epitopes and C-terminal hexa-histidine affinity tag is shown below.

Bold font; most hydrophobic epitopes of the set used as the first epitope in each triplet.

Italic font; most hydrophilic epitopes of the set used as the second epitope in each triplet.

Normal font; epitopes of set with mid-hydrophobicity used as the third epitope within each triplet.

HLA Type	EPITOPE	Hydropho-bicity (Hyd) (Pinsoft 2)	Rank ordered on Hyd and divided into 3 groups	Hyd	Optimised sequence	Hyd	Sum Hyd for triplets [HI, n=3]
A3	RLRPGGKKK	-0.26	**IPIVAIVALV**	0.98	**IPIVAIVALV**	0.98	
A*2402, A24, A23	KYKLKHIVW	0.44	**PLVKLWYQL**	0.8	*RLRPGGKKK*	-0.26	
B35	WASRELERF	0.22	**TWETWWTEYW**	0.76	ILKEPVHGV	0.44	1.16
B7, B8	RPGGKKKYKL	-0.16	**KLWVTVYYGV**	0.71	**PLVKLWYQL**	0.8	0.98
A2, A*0202, B62	SLYNTVATL	0.5	**VTLWQRPLV**	0.69	*RPGGKKKYKL*	-0.16	1.08
B8, B60	EIKDTKEAL	-0.02	**YTAFTIPSI**	0.69	KYKLKHIVW	0.44	1.08
A2, A*0202	TLNAWVKVV	0.57	**AIIRILQQL**	0.67	**TWETWWTEYW**	0.76	1.04
B7, B42, B53	TPQDLNTML	0.36	**LVGPTPVNI**	0.61	*EIKDTKEAL*	-0.02	1.18

TABLE 8 continued

A2	MTNNPPIPV	0.47	ALVEICTEM	0.59	KRWIILGLNK	0.45	1.19
B27	KRWIILGLNK	0.45	TLNAWVKVV	0.57	KLWVTVYYGV	0.71	1.14
A28, A74	VTLWQRPLV	0.69	YLAWVPAHK	0.57	*KIEELRQHL*	0.14	1.3
A2, A*0201	LVGPTPVNI	0.61	VIYQYMDDL	0.53	MTNNPPIPV	0.47	1.32
A2, A*0201	ALVEICTEM	0.59	SLYNTVATL	0.5	VTLWQRPLV	0.69	1.3
A2, B51	YTAFTIPSI	0.69	LLWKGEGAV	0.48	*WASRELERF*	0.22	1.38
A3, A11	AIFQSSMTK	0.35	MTNNPPIPV	0.47	LLWKGEGAV	0.48	1.39
A2, A*0201	VIYQYMDDL	0.53	KRWIILGLNK	0.45	YTAFTIPSI	0.69	1.39
A2, B60	KIEELRQHL	0.14	KYKLKHIVW	0.44	*IYQEPFKNLK*	0.27	1.44
A2	ILKEPVHGV	0.44	ILKEPVHGV	0.44	SLYNTVATL	0.5	1.46
A11	IYQEPFKNLK	0.27	*TPQDLNTML*	0.36	AIIRILQQL	0.67	1.44
B44	TWETWWTEYW	0.76	*AIFQSSMTK*	0.35	*AIFQSSMTK*	0.35	1.52
A2	PLVKLWYQL	0.8	*IYQEPFKNLK*	0.27	VIYQYMDDL	0.53	1.55
B7, A3	YLAWVPAHK	0.57	*WASRELERF*	0.22	LVGPTPVNI	0.61	1.49
A2, A*0201	LLWKGEGAV	0.48	*KIEELRQHL*	0.14	*TPQDLNTML*	0.36	1.5
A2, A*0201	AIIRILQQL	0.67	*EIKDTKEAL*	-0.02	YLAWVPAHK	0.57	1.54
B7	IPIVAIVALV	0.98	*RPGGKKKYKL*	-0.16	ALVEICTEM	0.59	1.52
A2, A2.1	KLWVTVYYGV	0.71	*RLRPGGKKK*	-0.26	TLNAWVKVV	0.57	1.73
			HHHHHH	0.04	HHHHHH	0.04	1.2

Example 4: HCV polyepitope fusions as vaccine candidates.

MATERIALS AND METHODS

Epitope sequences

The 26 CTL epitopes for inclusion in a HCV vaccine, the proteins from which they originate and HLA type are shown in Table 9.

Design/Ordering of epitopes

An ordered arrangement of CTL epitopes to produce a polyepitope sequence with favourable hydrophobicity characteristics was generated by the method described in Example1 (i) – (xi). The final shuffle involved taking CTCGSSDLY (SEQ ID NO:68) from position 3 and changing with FLLLADARV (SEQ.ID NO:69) at position 26 to reduce a high hydrophobic index (HI) which resulted from summing epitopes 24, 25 and 26. At the same time, five random sequences were generated and one of these (HCVb) was taken for comparison with the optimised sequence.

The ordering process for the optimised HCV polyepitope (HCVa) configuration is shown in Table 10.

Hydrophobic Index (HI) calculations

HI values for both configurations (HCVa and HCVb) were calculated according to the mathematical expression:-

$$HI_m = \sum_{e=m}^{e=m+n-1} x_e$$

(where m = group number, n = group size, e = integer (epitope) number, x = epitope hydophobicity value) over values of n from 2 to 5).

Generation of DNA constructs

Each polyepitope amino acid sequence was back translated to DNA using the Dnastar Editseq software and codons optimised for *E. coli* expression. C-terminal hexa-histidine tags were incorporated for purification and detection. The DNA encoding the polyepitope sequences was generated from synthetic oligonucleotides using a Splicing by Overlap Extension technique (SOE) as described by Horton et al (1995). These were cloned into pET24b (Novagen) and the resulting constructs sequenced to ensure that no errors

were present (Big Dye Terminator Kit V3.1; Applied Biosystems). For expression purposes, DNA was transformed into *E. coli* BL21(DE3) cells (Novagen).

Protein Expression and Analysis

Tranformed cells were grown at 37°C in Terrific Broth containing 50mg/ml Kanamycin. At an OD600 of ~2, protein expression was induced by addition of 0.5mM IPTG and samples taken at 1 hour, 2 hours, 3 hours and overnight post-induction. Cells were pelleted, resuspended to equal densities and boiled in SDS sample buffer prior to analysing by SDS-PAGE on Novex 4-20% Tris-Glycine gels. Gels were analysed both by Coomassie Blue staining and immunoblotting. Blots were probed with Dianova anti hexa-histidine monoclonal antibody.

RESULTS

Epitope fusions

26 HCV CTL epitopes were selected to provide the components of a vaccine formulation. In order to link these CTL epitopes (Table 7) together and facilitate the design of a polyepitope polypeptide to form the basis of a HCV vaccine, the hydrophobicity value of each epitope was calculated (as in the case of Example 1) using Pinsoft 2 software. Two versions of the 26 epitopes were then created (Figure 8), one which reduced peak hydrophobicity and hydrophobic sequence length (HCVa) and another in which the epitopes were randomly arranged (HCVb). These constructs were then assembled and cloned into *E. coli* for a comparison of their ability to produce a polyepitope polypeptide.

HCVa (optimised polyepitope)

While induced monomeric polyepitope polypeptide was not visible on Coomassie stained gels, protein of the predicted MW of 27.5kDa was detected at 2 and 3 hours post-induction when immunoblots were probed with the anti hexa-histidine antibody (Figures 9 and 10). Over time there was an increasing presence of high molecular weight products as a smear, indicating protein aggregation. After overnight induction these high molecular weight aggregates were also visible on the Coomassie stained gel (Figure 10).

HCVb (random polyepitope)

There was no detection of any induced monomeric polyepitope polypeptide either on Coomassie stained gels or by immunoblotting (Figures 9 and 10). Two faint bands were detected by immunoblotting after overnight induction, however these were at ~24 and

30kDa and were clearly not the predicted product of MW 27.5kDa. They most likely corresponded to two histidine-rich proteins of *E.coli*, rotamase (~23kDa; NCBI Accession NP_417808) and a protein of unknown function (~32kDa; NCBI Accession BAA15973). Since the former is a peptidyl-prolyl-isomerase involved in protein folding, it is perhaps not surprising that this should be overproduced in this situation.

DISCUSSION

In designing a HCV polyepitope, use of the above algorithm to order the 26 CTL epitopes has allowed the polypeptide sequence to be expressed, mainly as an aggregated product. On the other hand, expression of the polyepitope sequence which was randomly ordered failed to yield any detectable product.

TABLE 9: CTL epitopes included in the HCV polytopes

HLA Type	HCV Protein	Epitope
A2	NS1/E2	FLLLADARV (SEQ ID NO: 69)
A2	NS4	YLVAYQATV (SEQ ID NO: 70)
A2	NS5	RLIVFPDLGV (SEQ ID NO: 71)
A2	CORE	DLMGYIPLV (SEQ ID NO: 72)
A2	NS4	WMNRLIAFA (SEQ ID NO: 73)
A2	NS4	VLVGGVLAA (SEQ ID NO: 74)
A2	NS4	HMWNFISGI (SEQ ID NO: 75)
A2	NS4	ILAGYGAGV (SEQ ID NO: 76)
A2	CORE	YLLPRRGPRL (SEQ ID NO: 77)
A2	NS1/E2	LLFLLLADA (SEQ ID NO: 78)
A2	NS3	YLVTRHADV (SEQ ID NO: 79)
A3	CORE	KTSERSQPR (SEQ ID NO: 80)
A3	CORE	RLGVRATRK (SEQ ID NO: 81)
A3	ENV	QLFTFSPRR (SEQ ID NO: 82)
A3	NS1/E2	RMYVGGVEHR (SEQ ID NO: 83)
A3	NS3	LIFCHSKKK (SEQ ID NO: 84)
A3	NS4	GVAGALVAFK (SEQ ID NO: 85)
A3	NS4	VAGALVAFK (SEQ ID NO: 86)
A3	NS3	TLGFGAYMSK (SEQ ID NO: 87)
B7	CORE	LPGCSFSIF (SEQ ID NO: 88)
A1	NS5	LSAFSLHSY (SEQ ID NO: 89)
A1	NS3	CTCGSSDLY (SEQ ID NO: 68)
A24	NS4B	FWAKHMWNF (SEQ ID NO: 90)
A31	NS5	VGIYLLPNR (SEQ ID NO: 91)
A2	NS4	LLFNILGGWV (SEQ ID NO: 92)
B7	NS3	IPFYGKAI (SEQ ID NO: 93)

TABLE 10: Ordering process for generation of a polypepitope polypeptide for 26 HCV CTL epitopes (HCVa)

The hydrophobicity value for each epitope is calculated, then the epitopes are rank ordered, and grouped into triplets. The sequence is assessed using a hydrophobicity plot and scored for HI value by summing the epitope hydrophobicity values over a moving 3-mer window. If necessary, fine-tuning of the epitope order is done and the sequence is reassessed. The final epitope order and amino acid sequence for the 20 EBV CTL epitopes and C-terminal hexa-histidine affinity tag is shown below.

Bold font; most hydrophobic epitopes of the set used as the first epitope in each triplet.

Italic font; most hydrophilic epitopes of the set used as the second epitope in each triplet.

Normal font; epitopes of set with mid-hydrophobicity used as the third epitope within each triplet.

HLA Type	EPITOPE	Hydropho-bicity (Hyd) (Pinsoft 2)	Rank ordered on Hyd and divided into 3 groups	Hyd	Optimised sequence grouped into triplets	Hyd	Sum Hyd for triplets [HI, n=3]	Order after fine tuning (epitopes 3 & 26 swapped)	Hyd	Sum Hyd for triplets [HI, n=3]
A2	FLLLADARV	0.61	**LLFNILGGWV**	0.94	**LLFNILGGWV**	0.94		**LLFNILGGWV**	0.94	
A2	YLVAYQATV	0.58	**LLFLLLADA**	0.9	*KTSERSQPR*	-0.3		*KTSERSQPR*	-0.3	
A2	RLIVFPDLGV	0.67	**LPGCSFSIF**	0.82	CTCGSSDLY	0.44	1.08	FLLLADARV	0.61	1.25
A2	DLMGYIPLV	0.75	**DLMGYIPLV**	0.75	**LLFLLLADA**	0.9	1.04	**LLFLLLADA**	0.9	1.21
A2	WMNRLIAFA	0.68	**HMWNFISGI**	0.73	*RLGVRATRK*	-0.07	1.27	*RLGVRATRK*	-0.07	1.44
A2	VLVGGVLAA	0.67	**FWAKHMWNF**	0.72	GVAGALVAFK	0.47	1.30	GVAGALVAFK	0.47	1.30

TABLE 10 continued

A2	HMWNFISGI	0.73	WMNRLIAFA	0.68	LPGCSFSIF	0.82	1.22	LPGCSFSIF	0.82	1.22
A2	ILAGYGAGV	0.55	RLIVFPDLGV	0.67	*RMYVGGVEHR*	0.15	1.44	*RMYVGGVEHR*	0.15	1.44
A2	YLLPRRGPRL	0.35	VLVGGVLAA	0.67	VAGALVAFK	0.51	1.48	VAGALVAFK	0.51	1.48
A2	LLFLLLADA	0.9	FLLLADARV	0.61	DLMGYIPLV	0.75	1.41	DLMGYIPLV	0.75	1.41
A2	YLVTRHADV	0.34	IPFYGKAI	0.61	*LIFCHSKKK*	0.33	1.59	*LIFCHSKKK*	0.33	1.59
A3	KTSERSQPR	-0.3	YLVAYQATV	0.58	ILAGYGAGV	0.55	1.63	ILAGYGAGV	0.55	1.63
A3	RLGVRATRK	-0.07	LSAFSLHSY	0.56	HMWNFISGI	0.73	1.61	HMWNFISGI	0.73	1.61
A3	QLFTFSPRR	0.34	VGIYLLPNR	0.56	*QLFTFSPRR*	0.34	1.62	*QLFTFSPRR*	0.34	1.62
A3	RMYVGGVEHR	0.15	ILAGYGAGV	0.55	VGIYLLPNR	0.56	1.63	VGIYLLPNR	0.56	1.63
A3	LIFCHSKKK	0.33	VAGALVAFK	0.51	FWAKHMWNF	0.72	1.62	FWAKHMWNF	0.72	1.62
A3	GVAGALVAFK	0.47	GVAGALVAFK	0.47	*YLVTRHADV*	0.34	1.62	*YLVTRHADV*	0.34	1.62
A3	VAGALVAFK	0.51	CTCGSSDLY	0.44	LSAFSLHSY	0.56	1.62	LSAFSLHSY	0.56	1.62
A3	TLGFGAYMSK	0.41	*TLGFGAYMSK*	0.41	WMNRLIAFA	0.68	1.58	WMNRLIAFA	0.68	1.58
B7	LPGCSFSIF	0.82	*YLLPRRGPRL*	0.35	*YLLPRRGPRL*	0.35	1.59	*YLLPRRGPRL*	0.35	1.59
A1	LSAFSLHSY	0.56	*YLVTRHADV*	0.34	YLVAYQATV	0.58	1.61	YLVAYQATV	0.58	1.61
A1	CTCGSSDLY	0.44	*QLFTFSPRR*	0.34	RLIVFPDLGV	0.67	1.60	RLIVFPDLGV	0.67	1.60
A24	FWAKHMWNF	0.72	*LIFCHSKKK*	0.33	*TLGFGAYMSK*	0.41	1.66	*TLGFGAYMSK*	0.41	1.66
A31	VGIYLLPNR	0.56	*RMYVGGVEHR*	0.15	IPFYGKAI	0.61	1.69	IPFYGKAI	0.61	1.69
A2	LLFNILGGWV	0.94	*RLGVRATRK*	-0.07	VLVGGVLAA	0.67	1.69	VLVGGVLAA	0.67	1.69
B7	IPFYGKAI	0.61	*KTSERSQPR*	-0.3	FLLLADARV	0.61	1.89	CTCGSSDLY	0.44	1.72
			HHHHHH	0.04	HHHHHH	0.04	1.32	HHHHHH	0.04	1.15

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

References:

Elliot S.L., Pye S., Le T. et al. Peptide based cytotoxic T-cell vaccines; Delivery of multiple epitopes, help, memory and problems. Vaccine 1999; 17:2009-2019.

Fauchere J.-L and Pliska V.E. (1983), Eur. J. Med. Chem. 18:369-375.

Fisher M-T, Yuan X. The rates of commitment to renaturation of rhodanese and glutamine synthetase in the presence of the groE chaperonins. J. Bio. Chem. 1994 Nov 25; 269(47): 29598-601.

Frace A-M, Klimov A-I, rowe T, Black R-A, Katz J-M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine. 1999 May; 17(18): 2237-44.

Hayer-Hartl M-K, Ewbank J-J, Creighton T-E, Hartl F-U. Conformational specificity of the chaperonin GroEL for the compact folding intermediates of alpha-lactalbumin. EMBO J. 1994 Jul; 13(13): 3192-202.

Hendrick J-P, Hartl F-U. The role of molecular chaperones in protein folding. FASEB J. 1995 Dec; 9(15): 1559-69.

Hobman T-C, Seto N-O, Gillam S. Expression of soluble forms of rubella virus glycoproteins in mammalian cells. Virus-Res. 1994 Mar; 31(3): 277-89.

Hopp T.P., Woods K.R. Proc. Nat. Acad. Sci USA 1981; 78:3824-3828.

Horton R-M, Cai Z-L, Ho S-N, Pease L-R. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques, 1990; 528-35.

Lin Z, Schwartz F-P, Eisenstein E. The hydrophobic nature of GroEL substrate binding. J. Biol. Chem. 1995 ; 270(3): 1011-4.

Murali-Krishna K., Altman J.D., Suresh M. et al. Counting antigen specific CD8 T-cells; A re-evaluation of bystander activation during viral activation. Immunity 1998; 8:177-187.

Polte T, Newman W, Raghunathan G, Gopal TV. Structural and functional studies of full-length vascular cell adhesion molecule – 1: internal duplication and homology to several adhesion proteins. DNA Cell Biol. 1991; 10(5): 349-57

Richarme G, Kohiyama M. Amino acid specificity of the Escherichia coli chaperone GroEL (heat shock protein 60). J. Biol. Chem. 1994 Mar 11; 269(10): 7095-8.

Thuy TT Le et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMS. Vaccine 2001 19:4669-4675.

Wada K, Wada Y, Ishibashi F, Gojobori T, Ikemura T. Codon usage tabulated from the Gen Bank genetic sequence data. Nucleic Acids Research 1992 20 Suppl:2111-8

Zahn R, Pluckthun A. Thermodynamic partitioning model for hydrophobic binding of polypeptides by GroEL. II. GroEL recognizes thermally unfolded mature beta-lactamase. J. Mol. Biol. 1994 Sep 16; 242(2): 165-74.

Claims:

1. A method for designing a candidate polypeptide for expression in a suitable host, said method comprising,

identifying one or more hydrophobic peptide sequences within a polypeptide of interest, and

arranging or re-locating at least one of said hydrophobic peptide sequences within said polypeptide so as to generate said candidate polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s).

2. The method of claim 1, wherein the polypeptide of interest is to be expressed in a bacterial host.

3. The method of claim 1 or 2, wherein the bacterial host is *E. coli*.

4. The method of claim 3, wherein the polypeptide is non-native to *E. coli*.

5. The method of any one of the preceding claims, wherein the polypeptide of interest comprises a non-natural polypeptide or a theoretical non-natural polypeptide.

6. The method of claim 5, wherein the polypeptide comprises a polyepitope polypeptide comprising a tandem array of epitopes of interest.

7. A method for designing a candidate polyepitope polypeptide comprising a tandem array of epitopes for expression in a suitable host, said method comprising,

identifying the relative hydrophobicity of each of said epitopes,

dividing said epitopes on the basis of said identified hydrophobicities into groups of substantially equivalent numbers, said groups comprising at least a first group of epitopes of most relative hydrophobicity and a second group of epitopes of least relative hydrophobicity, and

arranging epitopes from said first and second groups in a substantially alternating manner so as to generate said candidate polyepitope polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s).

8. A method for designing a candidate polyepitope polypeptide comprising a tandem array of epitopes for expression in a suitable host, said method comprising,

identifying the relative hydrophobicity of each of said epitopes,

dividing said epitopes on the basis of said identified hydrophobicities into three groups of substantially equivalent numbers, said groups comprising a first group of epitopes of most hydrophobicity, a second group of epitopes of intermediate relative hydrophobicity, and a third group of epitopes of least relative hydrophobicity,

arranging epitopes from said first, second and third groups into triplets containing an epitope from each group, and

arranging said triplets in a linked sequence so as to generate said candidate polyepitope polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s).

9. A method for designing a candidate polyepitope polypeptide comprising a tandem array of epitopes for expression in a suitable host, said method comprising,

identifying the relative hydrophobicity of each of said epitopes,

dividing said epitopes on the basis of said identified hydrophobicities into four groups of substantially equivalent numbers, said groups comprising a first group of epitopes of most hydrophobicity, a second group of epitopes of lesser relative hydrophobicity, a third group of epitopes of even lesser relative hydrophobicity, and a fourth group of least relative hydrophobicity

arranging epitopes from said first, second and third groups into quadruplets containing an epitope from each group, and

arranging said quadruplets in a linked sequence so as to generate said candidate polyepitope polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s).

10. The method of any one of claims 7 to 9, wherein the polyepitope polypeptide comprises 5 to 100 epitopes.

11. The method of any one of claims 7 to 9, wherein the polyepitope polypeptide comprises 10 to 35 epitopes.

12. The method of any one of claims 7 to 11, wherein the epitopes comprising the polyepitope polypeptide are selected from epitopes of any one of the viruses of the group consisting of Epstein-Barr virus (EBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and cytomegalovirus (CMV).

13. A method of expressing a polypeptide in a suitable host, said method comprising,

designing a polypeptide in accordance with the method of any one of claims 1 to 12,

introducing a polynucleotide encoding said polypeptide into said host, such that said host is capable of expressing said polypeptide, and

culturing said bacterial host under conditions suitable for expression of said polypeptide.

14. A polypeptide designed in accordance with the method of any one of claims 1 to 5.

15. A polyepitope polypeptide designed in accordance with the method of any one of claims 1 to 12.

16. A polyepitope polypeptide comprising N epitopes, wherein N is any integer, said polyepitope polypeptide having the formula;

Triplet 1 - Triplet 2 - .... - Triplet N/3,

wherein each of said triplets comprises three linked epitopes selected by,

identifying and ranking the relative hydrophobicity of each of the N epitopes,

grouping the ranked N epitopes into three groups of substantially equivalent numbers, based upon the identified relative hydrophobicity of the N epitopes, to produce a first group comprising the epitopes of most relative hydrophobicity, a second group of epitopes of intermediate relative hydrophobicity, and a third group of epitopes of least relative hydrophobicity, and

selecting the epitopes for each of said triplets according to the following table:

	Epitope 1	Epitope 2	Epitope 3
Triplet 1 (N-terminal)	Most hydrophilic of Group 2	Most hydrophobic of Group 1	Most hydrophilic of Group 3
Triplet 2	2nd most hydrophilic of Group 2	2nd most hydrophobic of Group 1	2nd most hydrophilic of Group 3
Triplet N/3 (C-terminal)	Most hydrophobic of Group 2	Most hydrophilic of Group 1	Most hydrophobic of Group 3

17. The polyepitope polypeptide of claim 15 or 16, wherein the epitopes are contiguous or spaced apart by intervening sequences which are substantially free of sequences which naturally flank said epitopes.

18. A polypeptide vaccine comprising a polyepitope polypeptide according to any one of claims 14 to 17 and a pharmaceutically acceptable carrier and/or adjuvant.

19. A polyepitope polypeptide comprising an amino acid sequence substantially corresponding to an amino acid sequence selected from the group consisting of:

FLRGRAYGL – PYLFWLAAI – HRCQAIRKK – RRIYDLIEL – VQPPQLTLQV-GLCTLVAML - RLRAEAQVK -IEDPPFNSL –YLLEMLWRL – GQGGSPTAM - AVLLHEESM - IALYLQQNWWTL-RAKFKQLL - SSCSSCPLSKI- TYGPVFMCL-QAKWRLQTL - RPPIFIRRL- VSFIEFVGW - YPLHEQHGM –VEITPYKPTW - CLGGLLTMV – EENLLDFVRF - TYSAGIVQI – LLDFVRFMGV -EGGVGWRHW (SEQ ID NO:1),

FLRGRAYGL - PYLFWLAAI – HRCQAIRKK – RRIYDLIEL – GLCTLVAML – RLRAEAQVK - IEDPPFNSL –TYSAGIVQI - LLDFVRFMGV - EGGVGWRHW - IALYLQQNWWTL - RAKFKQLL – SSCSSCPLSKI - TYGPVFMCL - QAKWRLQTL-RPPIFIRRL - VSFIEFVGW – YPLHEQHGM – VEITPYKPTW – CLGGLLTMV – EENLLDFVRF - YLLEMLWRL – GQGGSPTAM - AVLLHEESM – VQPPQLTLQV (SEQ ID NO:2),

SSCSSCPLSKI – HRCQAIRKK – CLGGLLTMV – LTAGFLIFL – RLRAEAQVK – IEDPPFNSL – LLSAWILTA – RRRWRRLTV - PYLFWLAAI – YLLEMLWRL – GQGGSPTAM – VMSNTLLSAW – ALLVLYSFA – RAKFKQLL – IALYLQQNW – TYGPVFMCL - QAKWRLQTL – YLQQNWWTL – YPLHEQHGM – CPLSKILL (SEQ ID NO:3),

IPIVAIVALV – RLRPGGKKK – ILKEPVHGV – PLVKLWYQL – RPGGKKKYKL – KYKLKHIVW – TWETWWTEYW – EIKDTKEAL – KRWIILGLNK - KLWVTVYYGV – KIEELRQHL – MTNNPPIPV – VTLWQRPLV – WASRELERF – LLWKGEGAV – YTAFTIPSI – IYQEPFKNLK – SLYNTVATL – AIIRILQQL – AIFQSSMTK – VIYQYMDDL – LVGPTPVNI – TPQDLNTML – YLAWVPAHK – ALVEICTEM – TLNAWVKVV (SEQ ID NO:4),

and

LLFNILGGWV – KTSERSQPR – FLLLADARV – LLFLLLADA – RLGVRATRK – GVAGALVAFK – LPGCSFSIF – RMYVGGVEHR – VAGALVAFK – DLMGYIPLV – LIFCHSKKK – ILAGYGAGV – HMWNFISGI – QLFTFSPRR – VGIYLLPNR – FWAKHMWNF – YLVTRHADV – LSAFSLHSY – WMNRLIAFA – YLLPRRGPRL – YLVAYQATV – RLIVFPDLGV – TLGFGAYMSK – IPFYGKAI – VLVGGVLAA – CTCGSSDLY (SEQ ID NO:5).

20. The polyepitope polypeptide of claim 19, wherein the polyepitope polypeptide comprises an amino acid sequence substantially corresponding to:

FLRGRAYGL – PYLFWLAAI – HRCQAIRKK – RRIYDLIEL – VQPPQLTLQV-GLCTLVAML - RLRAEAQVK -IEDPPFNSL –YLLEMLWRL – GQGGSPTAM - AVLLHEESM - IALYLQQNWWTL-RAKFKQLL - SSCSSCPLSKI- TYGPVFMCL-QAKWRLQTL - RPPIFIRRL- VSFIEFVGW - YPLHEQHGM –VEITPYKPTW - CLGGLLTMV – EENLLDFVRF - TYSAGIVQI – LLDFVRFMGV -EGGVGWRHW (SEQ ID NO:1).

21. The polyepitope polypeptide of claim 19, wherein the polyepitope polypeptide comprises an amino acid sequence substantially corresponding to:

FLRGRAYGL - PYLFWLAAI – HRCQAIRKK – RRIYDLIEL – GLCTLVAML – RLRAEAQVK - IEDPPFNSL –TYSAGIVQI - LLDFVRFMGV - EGGVGWRHW - IALYLQQNWWTL - RAKFKQLL – SSCSSCPLSKI - TYGPVFMCL - QAKWRLQTL-RPPIFIRRL - VSFIEFVGW – YPLHEQHGM – VEITPYKPTW – CLGGLLTMV – EENLLDFVRF - YLLEMLWRL – GQGGSPTAM - AVLLHEESM – VQPPQLTLQV (SEQ ID NO:2).

22. The polyepitope polypeptide of claim 19, wherein the polyepitope polypeptide comprises an amino acid sequence substantially corresponding to:

SSCSSCPLSKI – HRCQAIRKK – CLGGLLTMV – LTAGFLIFL – RLRAEAQVK – IEDPPFNSL – LLSAWILTA – RRRWRRLTV - PYLFWLAAI – YLLEMLWRL – GQGGSPTAM – VMSNTLLSAW – ALLVLYSFA – RAKFKQLL – IALYLQQNW – TYGPVFMCL - QAKWRLQTL – YLQQNWWTL – YPLHEQHGM – CPLSKILL (SEQ ID NO:3).

23. The polyepitope polypeptide of claim 19, wherein the polyepitope polypeptide comprises an amino acid sequence substantially corresponding to:

IPIVAIVALV – RLRPGGKKK – ILKEPVHGV – PLVKLWYQL – RPGGKKKYKL – KYKLKHIVW – TWETWWTEYW – EIKDTKEAL – KRWIILGLNK - KLWVTVYYGV – KIEELRQHL – MTNNPPIPV – VTLWQRPLV – WASRELERF – LLWKGEGAV – YTAFTIPSI – IYQEPFKNLK – SLYNTVATL – AIIRILQQL – AIFQSSMTK – VIYQYMDDL – LVGPTPVNI – TPQDLNTML – YLAWVPAHK – ALVEICTEM – TLNAWVKVV (SEQ ID NO:4).

24. The polyepitope polypeptide of claim 19, wherein the polyepitope polypeptide comprises an amino acid sequence substantially corresponding to:

LLFNILGGWV – KTSERSQPR – FLLLADARV – LLFLLLADA – RLGVRATRK – GVAGALVAFK – LPGCSFSIF – RMYVGGVEHR – VAGALVAFK – DLMGYIPLV – LIFCHSKKK – ILAGYGAGV – HMWNFISGI – QLFTFSPRR – VGIYLLPNR – FWAKHMWNF – YLVTRHADV – LSAFSLHSY – WMNRLIAFA – YLLPRRGPRL – YLVAYQATV – RLFVFPDLGV – TLGFGAYMSK – IPFYGKAI – VLVGGVLAA – CTCGSSDLY (SEQ ID NO:5).

25. A polypeptide vaccine comprising a polyepitope polypeptide according to any one of claims 19 to 24 and a pharmaceutically acceptable carrier and/or adjuvant.

26. A viral or DNA vaccine comprising a polynucleotide encoding a polypeptide designed in accordance with the method of any one of claims 1 to 12 and a pharmaceutically acceptable carrier and/or adjuvant.

27. A viral or DNA vaccine comprising a polynucleotide encoding a polypeptide according to any one of claims 19 to 24 and a pharmaceutically acceptable carrier and/or adjuvant.

AMENDED CLAIMS

[(received by the International Bureau on 12 November 2003 (12.11.03); original claim 13 amended; remaining claims unchanged (1 page)]

12. The method of any one of claims 7 to 11, wherein the epitopes comprising the polyepitope polypeptide are selected from epitopes of any one of the viruses of the group consisting of Epstein-Barr virus (EBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and cytomegalovirus (CMV).

13. A method of expressing a polypeptide in a suitable host, said method comprising,

designing a polypeptide in accordance with the method of any one of claims 1 to 12,

introducing a polynucleotide encoding said polypeptide into said host, such that said host is capable of expressing said polypeptide, and

culturing said host under conditions suitable for expression of said polypeptide.

14. A polypeptide designed in accordance with the method of any one of claims 1 to 5.

15. A polyepitope polypeptide designed in accordance with the method of any one of claims 1 to 12.

16. A polyepitope polypeptide comprising N epitopes, wherein N is any integer, said polyepitope polypeptide having the formula;

Triplet 1 - Triplet 2 - .... - Triplet N/3,

wherein each of said triplets comprises three linked epitopes selected by,

identifying and ranking the relative hydrophobicity of each of the N epitopes,

grouping the ranked N epitopes into three groups of substantially equivalent numbers, based upon the identified relative hydrophobicity of the N epitopes, to produce a first group comprising the epitopes of most relative hydrophobicity, a second group of epitopes of intermediate relative hydrophobicity, and a third group of epitopes of least relative hydrophobicity, and

selecting the epitopes for each of said triplets according to the following table:

Sequence Listing:

<110> CSL Ltd and The Council of the Queensland Institute of Medical Research
<120> Expression of hydrophobic proteins
<130> 13455734
<150> AU2002950183
<151> 2002-07-12
<160> 102
<170> PatentIn version 3.1

<210> 1
<211> 233
<212> PRT
<213> epstein-barr virus (EBV)
<400> 1

```
Phe Leu Arg Gly Arg Ala Tyr Gly Leu Pro Tyr Leu Phe Trp Leu Ala
1               5                  10                  15

Ala Ile His Arg Cys Gln Ala Ile Arg Lys Lys Arg Arg Ile Tyr Asp
            20                  25                  30

Leu Ile Glu Leu Val Gln Pro Pro Gln Leu Thr Leu Gln Val Gly Leu
        35                  40                  45

Cys Thr Leu Val Ala Met Leu Arg Leu Arg Ala Glu Ala Gln Val Lys
    50                  55                  60

Ile Glu Asp Pro Pro Phe Asn Ser Leu Tyr Leu Leu Glu Met Leu Trp
65                  70                  75                  80

Arg Leu Gly Gln Gly Gly Ser Pro Thr Ala Met Ala Val Leu Leu His
                85                  90                  95

Glu Glu Ser Met Ile Ala Leu Tyr Leu Gln Gln Asn Trp Trp Thr Leu
            100                 105                 110

Arg Ala Lys Phe Lys Gln Leu Leu Ser Ser Cys Ser Ser Cys Pro Leu
        115                 120                 125

Ser Lys Ile Thr Tyr Gly Pro Val Phe Met Cys Leu Gln Ala Lys Trp
    130                 135                 140

Arg Leu Gln Thr Leu Arg Pro Pro Ile Phe Ile Arg Arg Leu Val Ser
145                 150                 155                 160

Phe Ile Glu Phe Val Gly Trp Tyr Pro Leu His Glu Gln His Gly Met
                165                 170                 175

Val Glu Ile Thr Pro Tyr Lys Pro Thr Trp Cys Leu Gly Gly Leu Leu
            180                 185                 190

Thr Met Val Glu Glu Asn Leu Leu Asp Phe Val Arg Phe Thr Tyr Ser
        195                 200                 205

Ala Gly Ile Val Gln Ile Leu Leu Asp Phe Val Arg Phe Met Gly Val
    210                 215                 220

Glu Gly Gly Val Gly Trp Arg His Trp
```

225 230

<210> 2
<211> 233
<212> PRT
<213> epstein-barr virus (EBV)
<400> 2

Phe Leu Arg Gly Arg Ala Tyr Gly Leu Pro Tyr Leu Phe Trp Leu Ala
1 5 10 15

Ala Ile His Arg Cys Gln Ala Ile Arg Lys Lys Arg Arg Ile Tyr Asp
20 25 30

Leu Ile Glu Leu Gly Leu Cys Thr Leu Val Ala Met Leu Arg Leu Arg
35 40 45

Ala Glu Ala Gln Val Lys Ile Glu Asp Pro Pro Phe Asn Ser Leu Thr
50 55 60

Tyr Ser Ala Gly Ile Val Gln Ile Leu Leu Asp Phe Val Arg Phe Met
65 70 75 80

Gly Val Glu Gly Gly Val Gly Trp Arg His Trp Ile Ala Leu Tyr Leu
85 90 95

Gln Gln Asn Trp Trp Thr Leu Arg Ala Lys Phe Lys Gln Leu Leu Ser
100 105 110

Ser Cys Ser Ser Cys Pro Leu Ser Lys Ile Thr Tyr Gly Pro Val Phe
115 120 125

Met Cys Leu Gln Ala Lys Trp Arg Leu Gln Thr Leu Arg Pro Pro Ile
130 135 140

Phe Ile Arg Arg Leu Val Ser Phe Ile Glu Phe Val Gly Trp Tyr Pro
145 150 155 160

Leu His Glu Gln His Gly Met Val Glu Ile Thr Pro Tyr Lys Pro Thr
165 170 175

Trp Cys Leu Gly Gly Leu Leu Thr Met Val Glu Glu Asn Leu Leu Asp
180 185 190

Phe Val Arg Phe Tyr Leu Leu Glu Met Leu Trp Arg Leu Gly Gln Gly
195 200 205

Gly Ser Pro Thr Ala Met Ala Val Leu Leu His Glu Glu Ser Met Val
210 215 220

Gln Pro Pro Gln Leu Thr Leu Gln Val
225 230

<210> 3
<211> 181
<212> PRT
<213> epstein-barr virus (EBV)
<400> 3

Ser Ser Cys Ser Ser Cys Pro Leu Ser Lys Ile His Arg Cys Gln Ala

1 5 10 15

Ile Arg Lys Lys Cys Leu Gly Gly Leu Leu Thr Met Val Leu Thr Ala
20 25 30

Gly Phe Leu Ile Phe Leu Arg Leu Arg Ala Glu Ala Gln Val Lys Ile
35 40 45

Glu Asp Pro Pro Phe Asn Ser Leu Leu Leu Ser Ala Trp Ile Leu Thr
50 55 60

Ala Arg Arg Arg Trp Arg Arg Leu Thr Val Pro Tyr Leu Phe Trp Leu
65 70 75 80

Ala Ala Ile Tyr Leu Leu Glu Met Leu Trp Arg Leu Gly Gln Gly Gly
85 90 95

Ser Pro Thr Ala Met Val Met Ser Asn Thr Leu Leu Ser Ala Trp Ala
100 105 110

Leu Leu Val Leu Tyr Ser Phe Ala Arg Ala Lys Phe Lys Gln Leu Leu
115 120 125

Ile Ala Leu Tyr Leu Gln Gln Asn Trp Thr Tyr Gly Pro Val Phe Met
130 135 140

Cys Leu Gln Ala Lys Trp Arg Leu Gln Thr Leu Tyr Leu Gln Gln Asn
145 150 155 160

Trp Trp Thr Leu Tyr Pro Leu His Glu Gln His Gly Met Cys Pro Leu
165 170 175

Ser Lys Ile Leu Leu
180

<210> 4
<211> 240
<212> PRT
<213> Human immunodeficiency virus
<400> 4

Ile Pro Ile Val Ala Ile Val Ala Leu Val Arg Leu Arg Pro Gly Gly
1 5 10 15

Lys Lys Lys Ile Leu Lys Glu Pro Val His Gly Val Pro Leu Val Lys
20 25 30

Leu Trp Tyr Gln Leu Arg Pro Gly Gly Lys Lys Lys Tyr Lys Leu Lys
35 40 45

Tyr Lys Leu Lys His Ile Val Trp Thr Trp Glu Thr Trp Trp Thr Glu
50 55 60

Tyr Trp Glu Ile Lys Asp Thr Lys Glu Ala Leu Lys Arg Trp Ile Ile
65 70 75 80

Leu Gly Leu Asn Lys Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Lys
85 90 95

Ile Glu Glu Leu Arg Gln His Leu Met Thr Asn Asn Pro Pro Ile Pro

100 105 110

Val Val Thr Leu Trp Gln Arg Pro Leu Val Trp Ala Ser Arg Glu Leu
115 120 125

Glu Arg Phe Leu Leu Trp Lys Gly Glu Gly Ala Val Tyr Thr Ala Phe
130 135 140

Thr Ile Pro Ser Ile Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Ser
145 150 155 160

Leu Tyr Asn Thr Val Ala Thr Leu Ala Ile Ile Arg Ile Leu Gln Gln
165 170 175

Leu Ala Ile Phe Gln Ser Ser Met Thr Lys Val Ile Tyr Gln Tyr Met
180 185 190

Asp Asp Leu Leu Val Gly Pro Thr Pro Val Asn Ile Thr Pro Gln Asp
195 200 205

Leu Asn Thr Met Leu Tyr Leu Ala Trp Val Pro Ala His Lys Ala Leu
210 215 220

Val Glu Ile Cys Thr Glu Met Thr Leu Asn Ala Trp Val Lys Val Val
225 230 235 240

<210> 5
<211> 239
<212> PRT
<213> Hepatitis C virus
<400> 5

Leu Leu Phe Asn Ile Leu Gly Gly Trp Val Lys Thr Ser Glu Arg Ser
1 5 10 15

Gln Pro Arg Phe Leu Leu Leu Ala Asp Ala Arg Val Leu Leu Phe Leu
20 25 30

Leu Leu Ala Asp Ala Arg Leu Gly Val Arg Ala Thr Arg Lys Gly Val
35 40 45

Ala Gly Ala Leu Val Ala Phe Lys Leu Pro Gly Cys Ser Phe Ser Ile
50 55 60

Phe Arg Met Tyr Val Gly Gly Val Glu His Arg Val Ala Gly Ala Leu
65 70 75 80

Val Ala Phe Lys Asp Leu Met Gly Tyr Ile Pro Leu Val Leu Ile Phe
85 90 95

Cys His Ser Lys Lys Lys Ile Leu Ala Gly Tyr Gly Ala Gly Val His
100 105 110

Met Trp Asn Phe Ile Ser Gly Ile Gln Leu Phe Thr Phe Ser Pro Arg
115 120 125

Arg Val Gly Ile Tyr Leu Leu Pro Asn Arg Phe Trp Ala Lys His Met
130 135 140

Trp Asn Phe Tyr Leu Val Thr Arg His Ala Asp Val Leu Ser Ala Phe

145 150 155 160

Ser Leu His Ser Tyr Trp Met Asn Arg Leu Ile Ala Phe Ala Tyr Leu
165 170 175

Leu Pro Arg Arg Gly Pro Arg Leu Tyr Leu Val Ala Tyr Gln Ala Thr
180 185 190

Val Arg Leu Ile Val Phe Pro Asp Leu Gly Val Thr Leu Gly Phe Gly
195 200 205

Ala Tyr Met Ser Lys Ile Pro Phe Tyr Gly Lys Ala Ile Val Leu Val
210 215 220

Gly Gly Val Leu Ala Ala Cys Thr Cys Gly Ser Ser Asp Leu Tyr
225 230 235

<210> 6
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 6

Cys Leu Gly Gly Leu Leu Thr Met Val
1 5

<210> 7
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 7

Gly Leu Cys Thr Leu Val Ala Met Leu
1 5

<210> 8
<211> 10
<212> PRT
<213> epstein-barr virus (EBV)
<400> 8

Leu Leu Asp Phe Val Arg Phe Met Gly Val
1 5 10

<210> 9
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 9

Tyr Leu Leu Glu Met Leu Trp Arg Leu
1 5

<210> 10
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 10

Tyr Leu Gln Gln Asn Trp Trp Thr Leu

1 5

<210> 11
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 11

Arg Leu Arg Ala Glu Ala Gln Val Lys
1 5

<210> 12
<211> 11
<212> PRT
<213> epstein-barr virus (EBV)
<400> 12

Ser Ser Cys Ser Ser Cys Pro Leu Ser Lys Ile
1 5 10

<210> 13
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 13

Pro Tyr Leu Phe Trp Leu Ala Ala Ile
1 5

<210> 14
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 14

Thr Tyr Gly Pro Val Phe Met Cys Leu
1 5

<210> 15
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 15

Thr Tyr Ser Ala Gly Ile Val Gln Ile
1 5

<210> 16
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 16

Arg Pro Pro Ile Phe Ile Arg Arg Leu
1 5

<210> 17
<211> 9
<212> PRT

<213> epstein-barr virus (EBV)
<400> 17

Phe Leu Arg Gly Arg Ala Tyr Gly Leu
1 5

<210> 18
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 18

Gln Ala Lys Trp Arg Leu Gln Thr Leu
1 5

<210> 19
<211> 8
<212> PRT
<213> epstein-barr virus (EBV)
<400> 19

Arg Ala Lys Phe Lys Gln Leu Leu
1 5

<210> 20
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 20

His Arg Cys Gln Ala Ile Arg Lys Lys
1 5

<210> 21
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 21

Arg Arg Ile Tyr Asp Leu Ile Glu Leu
1 5

<210> 22
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 22

Ala Val Leu Leu His Glu Glu Ser Met
1 5

<210> 23
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 23

Tyr Pro Leu His Glu Gln His Gly Met
1 5

<210> 24
<211> 10
<212> PRT
<213> epstein-barr virus (EBV)
<400> 24

Glu Glu Asn Leu Leu Asp Phe Val Arg Phe
1 5 10

<210> 25
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 25

Glu Gly Gly Val Gly Trp Arg His Trp
1 5

<210> 26
<211> 10
<212> PRT
<213> epstein-barr virus (EBV)
<400> 26

Val Glu Ile Thr Pro Tyr Lys Pro Thr Trp
1 5 10

<210> 27
<211> 10
<212> PRT
<213> epstein-barr virus (EBV)
<400> 27

Val Gln Pro Pro Gln Leu Thr Leu Gln Val
1 5 10

<210> 28
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 28

Ile Ala Leu Tyr Leu Gln Gln Asn Trp
1 5

<210> 29
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 29

Val Ser Phe Ile Glu Phe Val Gly Trp
1 5

<210> 30
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 30

Ile Glu Asp Pro Pro Phe Asn Ser Leu
1 5

<210> 31
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 31

Gly Gln Gly Gly Ser Pro Thr Ala Met
1 5

<210> 32
<211> 30
<212> DNA
<213> epstein-barr virus (EBV)
<400> 32

agggatccca tggaagatcc tggtttttttc 30

<210> 33
<211> 31
<212> DNA
<213> epstein-barr virus (EBV)
<400> 33

tctagaggtc gacacctgtc gttgtattgg g 31

<210> 34
<211> 12
<212> PRT
<213> epstein-barr virus (EBV)
<400> 34

Ile Ala Leu Tyr Leu Gln Gln Asn Trp Trp Thr Leu
1 5 10

<210> 35
<211> 6
<212> PRT
<213> Hexa-histidine tag
<400> 35

His His His His His His
1 5

<210> 36
<211> 10
<212> PRT
<213> epstein-barr virus (EBV)
<400> 36

Val Met Ser Asn Thr Leu Leu Ser Ala Trp
1 5 10

<210> 37
<211> 9
<212> PRT

<213> epstein-barr virus (EBV)
<400> 37

Leu Leu Ser Ala Trp Ile Leu Thr Ala
1 5

<210> 38
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 38

Leu Thr Ala Gly Phe Leu Ile Phe Leu
1 5

<210> 39
<211> 8
<212> PRT
<213> epstein-barr virus (EBV)
<400> 39

Cys Pro Leu Ser Lys Ile Leu Leu
1 5

<210> 40
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 40

Arg Arg Arg Trp Arg Arg Leu Thr Val
1 5

<210> 41
<211> 9
<212> PRT
<213> epstein-barr virus (EBV)
<400> 41

Ala Leu Leu Val Leu Tyr Ser Phe Ala
1 5

<210> 42
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 42

Arg Leu Arg Pro Gly Gly Lys Lys Lys
1 5

<210> 43
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 43

Lys Tyr Lys Leu Lys His Ile Val Trp
1 5

<210> 44
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 44

Trp Ala Ser Arg Glu Leu Glu Arg Phe
1 5

<210> 45
<211> 10
<212> PRT
<213> Human immunodeficiency virus
<400> 45

Arg Pro Gly Gly Lys Lys Lys Tyr Lys Leu
1 5 10

<210> 46
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 46

Ser Leu Tyr Asn Thr Val Ala Thr Leu
1 5

<210> 47
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 47

Glu Ile Lys Asp Thr Lys Glu Ala Leu
1 5

<210> 48
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 48

Thr Leu Asn Ala Trp Val Lys Val Val
1 5

<210> 49
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 49

Thr Pro Gln Asp Leu Asn Thr Met Leu
1 5

<210> 50
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 50

Met Thr Asn Asn Pro Pro Ile Pro Val
1 5

<210> 51
<211> 10
<212> PRT
<213> Human immunodeficiency virus
<400> 51

Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys
1 5 10

<210> 52
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 52

Val Thr Leu Trp Gln Arg Pro Leu Val
1 5

<210> 53
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 53

Leu Val Gly Pro Thr Pro Val Asn Ile
1 5

<210> 54
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 54

Ala Leu Val Glu Ile Cys Thr Glu Met
1 5

<210> 55
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 55

Tyr Thr Ala Phe Thr Ile Pro Ser Ile
1 5

<210> 56
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 56

Ala Ile Phe Gln Ser Ser Met Thr Lys
1 5

<210> 57
<211> 9
<212> PRT

<213> Human immunodeficiency virus
<400> 57

Val Ile Tyr Gln Tyr Met Asp Asp Leu
1 5

<210> 58
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 58

Lys Ile Glu Glu Leu Arg Gln His Leu
1 5

<210> 59
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 59

Ile Leu Lys Glu Pro Val His Gly Val
1 5

<210> 60
<211> 10
<212> PRT
<213> Human immunodeficiency virus
<400> 60

Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
1 5 10

<210> 61
<211> 10
<212> PRT
<213> Human immunodeficiency virus
<400> 61

Thr Trp Glu Thr Trp Trp Thr Glu Tyr Trp
1 5 10

<210> 62
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 62

Pro Leu Val Lys Leu Trp Tyr Gln Leu
1 5

<210> 63
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 63

Tyr Leu Ala Trp Val Pro Ala His Lys
1 5

<210> 64
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 64

Leu Leu Trp Lys Gly Glu Gly Ala Val
1 5

<210> 65
<211> 9
<212> PRT
<213> Human immunodeficiency virus
<400> 65

Ala Ile Ile Arg Ile Leu Gln Gln Leu
1 5

<210> 66
<211> 10
<212> PRT
<213> Human immunodeficiency virus
<400> 66

Ile Pro Ile Val Ala Ile Val Ala Leu Val
1 5 10

<210> 67
<211> 10
<212> PRT
<213> Human immunodeficiency virus
<400> 67

Lys Leu Trp Val Thr Val Tyr Tyr Gly Val
1 5 10

<210> 68
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 68

Cys Thr Cys Gly Ser Ser Asp Leu Tyr
1 5

<210> 69
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 69

Phe Leu Leu Leu Ala Asp Ala Arg Val
1 5

<210> 70
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 70

Tyr Leu Val Ala Tyr Gln Ala Thr Val
1 5

<210> 71
<211> 10
<212> PRT
<213> Hepatitis C virus
<400> 71

Arg Leu Ile Val Phe Pro Asp Leu Gly Val
1 5 10

<210> 72
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 72

Asp Leu Met Gly Tyr Ile Pro Leu Val
1 5

<210> 73
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 73

Trp Met Asn Arg Leu Ile Ala Phe Ala
1 5

<210> 74
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 74

Val Leu Val Gly Gly Val Leu Ala Ala
1 5

<210> 75
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 75

His Met Trp Asn Phe Ile Ser Gly Ile
1 5

<210> 76
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 76

Ile Leu Ala Gly Tyr Gly Ala Gly Val
1 5

<210> 77
<211> 10
<212> PRT

<213> Hepatitis C virus
<400> 77

Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu
1 5 10

<210> 78
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 78

Leu Leu Phe Leu Leu Leu Ala Asp Ala
1 5

<210> 79
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 79

Tyr Leu Val Thr Arg His Ala Asp Val
1 5

<210> 80
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 80

Lys Thr Ser Glu Arg Ser Gln Pro Arg
1 5

<210> 81
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 81

Arg Leu Gly Val Arg Ala Thr Arg Lys
1 5

<210> 82
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 82

Gln Leu Phe Thr Phe Ser Pro Arg Arg
1 5

<210> 83
<211> 10
<212> PRT
<213> Hepatitis C virus
<400> 83

Arg Met Tyr Val Gly Gly Val Glu His Arg
1 5 10

<210> 84
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 84

Leu Ile Phe Cys His Ser Lys Lys Lys
1 5

<210> 85
<211> 10
<212> PRT
<213> Hepatitis C virus
<400> 85

Gly Val Ala Gly Ala Leu Val Ala Phe Lys
1 5 10

<210> 86
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 86

Val Ala Gly Ala Leu Val Ala Phe Lys
1 5

<210> 87
<211> 10
<212> PRT
<213> Hepatitis C virus
<400> 87

Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys
1 5 10

<210> 88
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 88

Leu Pro Gly Cys Ser Phe Ser Ile Phe
1 5

<210> 89
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 89

Leu Ser Ala Phe Ser Leu His Ser Tyr
1 5

<210> 90
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 90

Phe Trp Ala Lys His Met Trp Asn Phe
1 5

<210> 91
<211> 9
<212> PRT
<213> Hepatitis C virus
<400> 91

Val Gly Ile Tyr Leu Leu Pro Asn Arg
1 5

<210> 92
<211> 10
<212> PRT
<213> Hepatitis C virus
<400> 92

Leu Leu Phe Asn Ile Leu Gly Gly Trp Val
1 5 10

<210> 93
<211> 8
<212> PRT
<213> Hepatitis C virus
<400> 93

Ile Pro Phe Tyr Gly Lys Ala Ile
1 5

<210> 94
<211> 242
<212> PRT
<213> epstein-barr virus (EBV)
<400> 94

Met Val Asp Phe Leu Arg Gly Arg Ala Tyr Gly Leu Pro Tyr Leu Phe
1 5 10 15

Trp Leu Ala Ala Ile His Arg Cys Gln Ala Ile Arg Lys Lys Arg Arg
20 25 30

Ile Tyr Asp Leu Ile Glu Leu Val Gln Pro Pro Gln Leu Thr Leu Gln
35 40 45

Val Gly Leu Cys Thr Leu Val Ala Met Leu Arg Leu Arg Ala Glu Ala
50 55 60

Gln Val Lys Ile Glu Asp Pro Pro Phe Asn Ser Leu Tyr Leu Leu Glu
65 70 75 80

Met Leu Trp Arg Leu Gly Gln Gly Gly Ser Pro Thr Ala Met Ala Val
85 90 95

Leu Leu His Glu Glu Ser Met Ile Ala Leu Tyr Leu Gln Gln Asn Trp
100 105 110

Trp Thr Leu Arg Ala Lys Phe Lys Gln Leu Leu Ser Ser Cys Ser Ser
115 120 125

Cys Pro Leu Ser Lys Ile Thr Tyr Gly Pro Val Phe Met Cys Leu Gln
130 135 140

Ala Lys Trp Arg Leu Gln Thr Leu Arg Pro Pro Ile Phe Ile Arg Arg
145 150 155 160

Leu Val Ser Phe Ile Glu Phe Val Gly Trp Tyr Pro Leu His Glu Gln
165 170 175

His Gly Met Val Glu Ile Thr Pro Tyr Lys Pro Thr Trp Cys Leu Gly
180 185 190

Gly Leu Leu Thr Met Val Glu Glu Asn Leu Leu Asp Phe Val Arg Phe
195 200 205

Thr Tyr Ser Ala Gly Ile Val Gln Ile Leu Leu Asp Phe Val Arg Phe
210 215 220

Met Gly Val Glu Gly Gly Val Gly Trp Arg His Trp His His His His
225 230 235 240

His His

<210> 95
<211> 242
<212> PRT
<213> epstein-barr virus (EBV)
<400> 95

Met Val Asp Phe Leu Arg Gly Arg Ala Tyr Gly Leu Pro Tyr Leu Phe
1 5 10 15

Trp Leu Ala Ala Ile His Arg Cys Gln Ala Ile Arg Lys Lys Arg Arg
20 25 30

Ile Tyr Asp Leu Ile Glu Leu Gly Leu Cys Thr Leu Val Ala Met Leu
35 40 45

Arg Leu Arg Ala Glu Ala Gln Val Lys Ile Glu Asp Pro Pro Phe Asn
50 55 60

Ser Leu Thr Tyr Ser Ala Gly Ile Val Gln Ile Leu Leu Asp Phe Val
65 70 75 80

Arg Phe Met Gly Val Glu Gly Gly Val Gly Trp Arg His Trp Ile Ala
85 90 95

Leu Tyr Leu Gln Gln Asn Trp Trp Thr Leu Arg Ala Lys Phe Lys Gln
100 105 110

Leu Leu Ser Ser Cys Ser Ser Cys Pro Leu Ser Lys Ile Thr Tyr Gly
115 120 125

Pro Val Phe Met Cys Leu Gln Ala Lys Trp Arg Leu Gln Thr Leu Arg
130 135 140

Pro Pro Ile Phe Ile Arg Arg Leu Val Ser Phe Ile Glu Phe Val Gly
145 150 155 160

Trp Tyr Pro Leu His Glu Gln His Gly Met Val Glu Ile Thr Pro Tyr
165 170 175

Lys Pro Thr Trp Cys Leu Gly Gly Leu Leu Thr Met Val Glu Glu Asn
180 185 190

Leu Leu Asp Phe Val Arg Phe Tyr Leu Leu Glu Met Leu Trp Arg Leu
195 200 205

Gly Gln Gly Gly Ser Pro Thr Ala Met Ala Val Leu Leu His Glu Glu
210 215 220

Ser Met Val Gln Pro Pro Gln Leu Thr Leu Gln Val His His His His
225 230 235 240

His His

<210> 96
<211> 669
<212> PRT
<213> epstein-barr virus (EBV)
<400> 96

Met Glu Asp Pro Gly Phe Phe Asn Val Glu Ile Pro Glu Phe Pro Phe
1 5 10 15

Tyr Pro Thr Cys Asn Val Cys Thr Ala Asp Val Asn Val Thr Ile Asn
20 25 30

Phe Asp Val Gly Gly Lys Lys His Gln Leu Asp Leu Asp Phe Gly Gln
35 40 45

Leu Thr Pro His Thr Lys Ala Val Tyr Gln Pro Arg Gly Ala Phe Gly
50 55 60

Gly Ser Glu Asn Ala Thr Asn Leu Phe Leu Leu Glu Leu Leu Gly Ala
65 70 75 80

Gly Glu Leu Ala Leu Thr Met Arg Ser Lys Lys Leu Pro Ile Asn Val
85 90 95

Thr Thr Gly Glu Glu Gln Gln Val Ser Leu Glu Ser Val Asp Val Tyr
100 105 110

Phe Gln Asp Val Phe Gly Thr Met Trp Cys His His Ala Glu Met Gln
115 120 125

Asn Pro Val Tyr Leu Ile Pro Glu Thr Val Pro Tyr Ile Lys Trp Asp
130 135 140

Asn Cys Asn Ser Thr Asn Ile Thr Ala Val Val Arg Ala Gln Gly Leu
145 150 155 160

Asp Val Thr Leu Pro Leu Ser Leu Pro Thr Ser Ala Gln Asp Ser Asn
165 170 175

Phe Ser Val Lys Thr Glu Met Leu Gly Asn Glu Ile Asp Ile Glu Cys
180 185 190

Ile Met Glu Asp Gly Glu Ile Ser Gln Val Leu Pro Gly Asp Asn Lys
195 200 205

Phe Asn Ile Thr Cys Ser Gly Tyr Glu Ser His Val Pro Ser Gly Gly
210 215 220

Ile Leu Thr Ser Thr Ser Pro Val Ala Thr Pro Ile Pro Gly Thr Gly
225 230 235 240

Tyr Ala Tyr Ser Leu Arg Leu Thr Pro Arg Pro Val Ser Arg Phe Leu
245 250 255

Gly Asn Asn Ser Ile Leu Tyr Val Phe Tyr Ser Gly Asn Gly Pro Lys
260 265 270

Ala Ser Gly Gly Asp Tyr Cys Ile Gln Ser Asn Ile Val Phe Ser Asp
275 280 285

Glu Ile Pro Ala Ser Gln Asp Met Pro Thr Asn Thr Thr Asp Ile Thr
290 295 300

Tyr Val Gly Asp Asn Ala Thr Tyr Ser Val Pro Met Val Thr Ser Glu
305 310 315 320

Asp Ala Asn Ser Pro Asn Val Thr Val Thr Ala Phe Trp Ala Trp Pro
325 330 335

Asn Asn Thr Glu Thr Asp Phe Lys Cys Lys Trp Thr Leu Thr Ser Gly
340 345 350

Thr Pro Ser Gly Cys Glu Asn Ile Ser Gly Ala Phe Ala Ser Asn Arg
355 360 365

Thr Phe Asp Ile Thr Val Ser Gly Leu Gly Thr Ala Pro Lys Thr Leu
370 375 380

Ile Ile Thr Arg Thr Ala Thr Asn Ala Thr Thr Thr Thr His Lys Val
385 390 395 400

Ile Phe Ser Lys Ala Pro Glu Ser Thr Thr Thr Ser Pro Thr Leu Asn
405 410 415

Thr Thr Gly Phe Ala Asp Pro Asn Thr Thr Thr Gly Val Asp Phe Leu
420 425 430

Arg Gly Arg Ala Tyr Gly Leu Pro Tyr Leu Phe Trp Leu Ala Ala Ile
435 440 445

His Arg Cys Gln Ala Ile Arg Lys Lys Arg Arg Ile Tyr Asp Leu Ile
450 455 460

Glu Leu Val Gln Pro Pro Gln Leu Thr Leu Gln Val Gly Leu Cys Thr
465 470 475 480

Leu Val Ala Met Leu Arg Leu Arg Ala Glu Ala Gln Val Lys Ile Glu
485 490 495

Asp Pro Pro Phe Asn Ser Leu Tyr Leu Leu Glu Met Leu Trp Arg Leu
500 505 510

Gly Gln Gly Gly Ser Pro Thr Ala Met Ala Val Leu Leu His Glu Glu
515 520 525

Ser Met Ile Ala Leu Tyr Leu Gln Gln Asn Trp Trp Thr Leu Arg Ala
530 535 540

Lys Phe Lys Gln Leu Leu Ser Ser Cys Ser Ser Cys Pro Leu Ser Lys
545 550 555 560

Ile Thr Tyr Gly Pro Val Phe Met Cys Leu Gln Ala Lys Trp Arg Leu
565 570 575

Gln Thr Leu Arg Pro Pro Ile Phe Ile Arg Arg Leu Val Ser Phe Ile
580 585 590

Glu Phe Val Gly Trp Tyr Pro Leu His Glu Gln His Gly Met Val Glu
595 600 605

Ile Thr Pro Tyr Lys Pro Thr Trp Cys Leu Gly Gly Leu Leu Thr Met
610 615 620

Val Glu Glu Asn Leu Leu Asp Phe Val Arg Phe Thr Tyr Ser Ala Gly
625 630 635 640

Ile Val Gln Ile Leu Leu Asp Phe Val Arg Phe Met Gly Val Glu Gly
645 650 655

Gly Val Gly Trp Arg His Trp His His His His His His His
660 665

<210> 97
<211> 669
<212> PRT
<213> epstein-barr virus (EBV)
<400> 97

Met Glu Asp Pro Gly Phe Phe Asn Val Glu Ile Pro Glu Phe Pro Phe
1 5 10 15

Tyr Pro Thr Cys Asn Val Cys Thr Ala Asp Val Asn Val Thr Ile Asn
20 25 30

Phe Asp Val Gly Gly Lys Lys His Gln Leu Asp Leu Asp Phe Gly Gln
35 40 45

Leu Thr Pro His Thr Lys Ala Val Tyr Gln Pro Arg Gly Ala Phe Gly
50 55 60

Gly Ser Glu Asn Ala Thr Asn Leu Phe Leu Leu Glu Leu Leu Gly Ala
65 70 75 80

Gly Glu Leu Ala Leu Thr Met Arg Ser Lys Lys Leu Pro Ile Asn Val
85 90 95

Thr Thr Gly Glu Glu Gln Gln Val Ser Leu Glu Ser Val Asp Val Tyr
100 105 110

Phe Gln Asp Val Phe Gly Thr Met Trp Cys His His Ala Glu Met Gln
115 120 125

```
Asn Pro Val Tyr Leu Ile Pro Glu Thr Val Pro Tyr Ile Lys Trp Asp
    130                 135                 140

Asn Cys Asn Ser Thr Asn Ile Thr Ala Val Val Arg Ala Gln Gly Leu
145                 150                 155                 160

Asp Val Thr Leu Pro Leu Ser Leu Pro Thr Ser Ala Gln Asp Ser Asn
                165                 170                 175

Phe Ser Val Lys Thr Glu Met Leu Gly Asn Glu Ile Asp Ile Glu Cys
            180                 185                 190

Ile Met Glu Asp Gly Glu Ile Ser Gln Val Leu Pro Gly Asp Asn Lys
        195                 200                 205

Phe Asn Ile Thr Cys Ser Gly Tyr Glu Ser His Val Pro Ser Gly Gly
    210                 215                 220

Ile Leu Thr Ser Thr Ser Pro Val Ala Thr Pro Ile Pro Gly Thr Gly
225                 230                 235                 240

Tyr Ala Tyr Ser Leu Arg Leu Thr Pro Arg Pro Val Ser Arg Phe Leu
                245                 250                 255

Gly Asn Asn Ser Ile Leu Tyr Val Phe Tyr Ser Gly Asn Gly Pro Lys
            260                 265                 270

Ala Ser Gly Gly Asp Tyr Cys Ile Gln Ser Asn Ile Val Phe Ser Asp
        275                 280                 285

Glu Ile Pro Ala Ser Gln Asp Met Pro Thr Asn Thr Thr Asp Ile Thr
    290                 295                 300

Tyr Val Gly Asp Asn Ala Thr Tyr Ser Val Pro Met Val Thr Ser Glu
305                 310                 315                 320

Asp Ala Asn Ser Pro Asn Val Thr Val Thr Ala Phe Trp Ala Trp Pro
                325                 330                 335

Asn Asn Thr Glu Thr Asp Phe Lys Cys Lys Trp Thr Leu Thr Ser Gly
            340                 345                 350

Thr Pro Ser Gly Cys Glu Asn Ile Ser Gly Ala Phe Ala Ser Asn Arg
        355                 360                 365

Thr Phe Asp Ile Thr Val Ser Gly Leu Gly Thr Ala Pro Lys Thr Leu
    370                 375                 380

Ile Ile Thr Arg Thr Ala Thr Asn Ala Thr Thr Thr Thr His Lys Val
385                 390                 395                 400

Ile Phe Ser Lys Ala Pro Glu Ser Thr Thr Thr Ser Pro Thr Leu Asn
                405                 410                 415

Thr Thr Gly Phe Ala Asp Pro Asn Thr Thr Thr Gly Val Asp Phe Leu
            420                 425                 430

Arg Gly Arg Ala Tyr Gly Leu Pro Tyr Leu Phe Trp Leu Ala Ala Ile
        435                 440                 445
```

His Arg Cys Gln Ala Ile Arg Lys Lys Arg Arg Ile Tyr Asp Leu Ile
450 455 460

Glu Leu Gly Leu Cys Thr Leu Val Ala Met Leu Arg Leu Arg Ala Glu
465 470 475 480

Ala Gln Val Lys Ile Glu Asp Pro Pro Phe Asn Ser Leu Thr Tyr Ser
485 490 495

Ala Gly Ile Val Gln Ile Leu Leu Asp Phe Val Arg Phe Met Gly Val
500 505 510

Glu Gly Gly Val Gly Trp Arg His Trp Ile Ala Leu Tyr Leu Gln Gln
515 520 525

Asn Trp Trp Thr Leu Arg Ala Lys Phe Lys Gln Leu Leu Ser Ser Cys
530 535 540

Ser Ser Cys Pro Leu Ser Lys Ile Thr Tyr Gly Pro Val Phe Met Cys
545 550 555 560

Leu Gln Ala Lys Trp Arg Leu Gln Thr Leu Arg Pro Pro Ile Phe Ile
565 570 575

Arg Arg Leu Val Ser Phe Ile Glu Phe Val Gly Trp Tyr Pro Leu His
580 585 590

Glu Gln His Gly Met Val Glu Ile Thr Pro Tyr Lys Pro Thr Trp Cys
595 600 605

Leu Gly Gly Leu Leu Thr Met Val Glu Glu Asn Leu Leu Asp Phe Val
610 615 620

Arg Phe Tyr Leu Leu Glu Met Leu Trp Arg Leu Gly Gln Gly Gly Ser
625 630 635 640

Pro Thr Ala Met Ala Val Leu Leu His Glu Glu Ser Met Val Gln Pro
645 650 655

Pro Gln Leu Thr Leu Gln Val His His His His His His
660 665

<210> 98
<211> 187
<212> PRT
<213> epstein-barr virus (EBV)
<400> 98

Ser Ser Cys Ser Ser Cys Pro Leu Ser Lys Ile His Arg Cys Gln Ala
1 5 10 15

Ile Arg Lys Lys Cys Leu Gly Gly Leu Leu Thr Met Val Leu Thr Ala
20 25 30

Gly Phe Leu Ile Phe Leu Arg Leu Arg Ala Glu Ala Gln Val Lys Ile
35 40 45

Glu Asp Pro Pro Phe Asn Ser Leu Leu Leu Ser Ala Trp Ile Leu Thr
50 55 60

Ala Arg Arg Arg Trp Arg Arg Leu Thr Val Pro Tyr Leu Phe Trp Leu
65 70 75 80

Ala Ala Ile Tyr Leu Leu Glu Met Leu Trp Arg Leu Gly Gln Gly Gly
85 90 95

Ser Pro Thr Ala Met Val Met Ser Asn Thr Leu Leu Ser Ala Trp Ala
100 105 110

Leu Leu Val Leu Tyr Ser Phe Ala Arg Ala Lys Phe Lys Gln Leu Leu
115 120 125

Ile Ala Leu Tyr Leu Gln Gln Asn Trp Thr Tyr Gly Pro Val Phe Met
130 135 140

Cys Leu Gln Ala Lys Trp Arg Leu Gln Thr Leu Tyr Leu Gln Gln Asn
145 150 155 160

Trp Trp Thr Leu Tyr Pro Leu His Glu Gln His Gly Met Cys Pro Leu
165 170 175

Ser Lys Ile Leu Leu His His His His His His
180 185

<210> 99
<211> 246
<212> PRT
<213> Human immunodeficiency virus
<400> 99

Ile Pro Ile Val Ala Ile Val Ala Leu Val Arg Leu Arg Pro Gly Gly
1 5 10 15

Lys Lys Lys Ile Leu Lys Glu Pro Val His Gly Val Pro Leu Val Lys
20 25 30

Leu Trp Tyr Gln Leu Arg Pro Gly Gly Lys Lys Lys Tyr Lys Leu Lys
35 40 45

Tyr Lys Leu Lys His Ile Val Trp Thr Trp Glu Thr Trp Trp Thr Glu
50 55 60

Tyr Trp Glu Ile Lys Asp Thr Lys Glu Ala Leu Lys Arg Trp Ile Ile
65 70 75 80

Leu Gly Leu Asn Lys Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Lys
85 90 95

Ile Glu Glu Leu Arg Gln His Leu Met Thr Asn Asn Pro Pro Ile Pro
100 105 110

Val Val Thr Leu Trp Gln Arg Pro Leu Val Trp Ala Ser Arg Glu Leu
115 120 125

Glu Arg Phe Leu Leu Trp Lys Gly Glu Gly Ala Val Tyr Thr Ala Phe
130 135 140

Thr Ile Pro Ser Ile Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Ser
145 150 155 160

Leu Tyr Asn Thr Val Ala Thr Leu Ala Ile Ile Arg Ile Leu Gln Gln
165 170 175

Leu Ala Ile Phe Gln Ser Ser Met Thr Lys Val Ile Tyr Gln Tyr Met
180 185 190

Asp Asp Leu Leu Val Gly Pro Thr Pro Val Asn Ile Thr Pro Gln Asp
195 200 205

Leu Asn Thr Met Leu Tyr Leu Ala Trp Val Pro Ala His Lys Ala Leu
210 215 220

Val Glu Ile Cys Thr Glu Met Thr Leu Asn Ala Trp Val Lys Val Val
225 230 235 240

His His His His His His
245

<210> 100
<211> 246
<212> PRT
<213> Human immunodeficiency virus
<400> 100

Ile Leu Lys Glu Pro Val His Gly Val Lys Arg Trp Ile Ile Leu Gly
1 5 10 15

Leu Asn Lys Thr Leu Asn Ala Trp Val Lys Val Val Lys Ile Glu Glu
20 25 30

Leu Arg Gln His Leu Tyr Thr Ala Phe Thr Ile Pro Ser Ile Trp Ala
35 40 45

Ser Arg Glu Leu Glu Arg Phe Pro Leu Val Lys Leu Trp Tyr Gln Leu
50 55 60

Leu Val Gly Pro Thr Pro Val Asn Ile Ile Pro Ile Val Ala Ile Val
65 70 75 80

Ala Leu Val Ser Leu Tyr Asn Thr Val Ala Thr Leu Met Thr Asn Asn
85 90 95

Pro Pro Ile Pro Val Leu Leu Trp Lys Gly Glu Gly Ala Val Thr Trp
100 105 110

Glu Thr Trp Trp Thr Glu Tyr Trp Ala Ile Phe Gln Ser Ser Met Thr
115 120 125

Lys Arg Leu Arg Pro Gly Gly Lys Lys Lys Ala Leu Val Glu Ile Cys
130 135 140

Thr Glu Met Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Tyr Leu Ala
145 150 155 160

Trp Val Pro Ala His Lys Ala Ile Ile Arg Ile Leu Gln Gln Leu Glu
165 170 175

Ile Lys Asp Thr Lys Glu Ala Leu Val Thr Leu Trp Gln Arg Pro Leu
180 185 190

Val Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Val Ile Tyr Gln Tyr
195 200 205

Met Asp Asp Leu Thr Pro Gln Asp Leu Asn Thr Met Leu Arg Pro Gly
210 215 220

Gly Lys Lys Lys Tyr Lys Leu Lys Tyr Lys Leu Lys His Ile Val Trp
225 230 235 240

His His His His His His
245

<210> 101
<211> 245
<212> PRT
<213> Hepatitis C virus
<400> 101

Leu Leu Phe Asn Ile Leu Gly Gly Trp Val Lys Thr Ser Glu Arg Ser
1 5 10 15

Gln Pro Arg Phe Leu Leu Leu Ala Asp Ala Arg Val Leu Leu Phe Leu
20 25 30

Leu Leu Ala Asp Ala Arg Leu Gly Val Arg Ala Thr Arg Lys Gly Val
35 40 45

Ala Gly Ala Leu Val Ala Phe Lys Leu Pro Gly Cys Ser Phe Ser Ile
50 55 60

Phe Arg Met Tyr Val Gly Gly Val Glu His Arg Val Ala Gly Ala Leu
65 70 75 80

Val Ala Phe Lys Asp Leu Met Gly Tyr Ile Pro Leu Val Leu Ile Phe
85 90 95

Cys His Ser Lys Lys Lys Ile Leu Ala Gly Tyr Gly Ala Gly Val His
100 105 110

Met Trp Asn Phe Ile Ser Gly Ile Gln Leu Phe Thr Phe Ser Pro Arg
115 120 125

Arg Val Gly Ile Tyr Leu Leu Pro Asn Arg Phe Trp Ala Lys His Met
130 135 140

Trp Asn Phe Tyr Leu Val Thr Arg His Ala Asp Val Leu Ser Ala Phe
145 150 155 160

Ser Leu His Ser Tyr Trp Met Asn Arg Leu Ile Ala Phe Ala Tyr Leu
165 170 175

Leu Pro Arg Arg Gly Pro Arg Leu Tyr Leu Val Ala Tyr Gln Ala Thr
180 185 190

Val Arg Leu Ile Val Phe Pro Asp Leu Gly Val Thr Leu Gly Phe Gly
195 200 205

Ala Tyr Met Ser Lys Ile Pro Phe Tyr Gly Lys Ala Ile Val Leu Val
210 215 220

Gly Gly Val Leu Ala Ala Cys Thr Cys Gly Ser Ser Asp Leu Tyr His
225 230 235 240

His His His His His
245

<210> 102
<211> 245
<212> PRT
<213> Hepatitis C virus
<400> 102

Tyr Leu Val Thr Arg His Ala Asp Val Trp Met Asn Arg Leu Ile Ala
1 5 10 15

Phe Ala Cys Thr Cys Gly Ser Ser Asp Leu Tyr Val Gly Ile Tyr Leu
20 25 30

Leu Pro Asn Arg Ile Leu Ala Gly Tyr Gly Ala Gly Val Leu Ile Phe
35 40 45

Cys His Ser Lys Lys Lys His Met Trp Asn Phe Ile Ser Gly Ile Phe
50 55 60

Leu Leu Leu Ala Asp Ala Arg Val Leu Leu Phe Leu Leu Leu Ala Asp
65 70 75 80

Ala Leu Ser Ala Phe Ser Leu His Ser Tyr Gly Val Ala Gly Ala Leu
85 90 95

Val Ala Phe Lys Lys Thr Ser Glu Arg Ser Gln Pro Arg Arg Leu Gly
100 105 110

Val Arg Ala Thr Arg Lys Asp Leu Met Gly Tyr Ile Pro Leu Val Val
115 120 125

Leu Val Gly Gly Val Leu Ala Ala Leu Leu Phe Asn Ile Leu Gly Gly
130 135 140

Trp Val Tyr Leu Val Ala Tyr Gln Ala Thr Val Tyr Leu Leu Pro Arg
145 150 155 160

Arg Gly Pro Arg Leu Phe Trp Ala Lys His Met Trp Asn Phe Gln Leu
165 170 175

Phe Thr Phe Ser Pro Arg Arg Leu Pro Gly Cys Ser Phe Ser Ile Phe
180 185 190

Ile Pro Phe Tyr Gly Lys Ala Ile Arg Met Tyr Val Gly Gly Val Glu
195 200 205

His Arg Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Arg Leu Ile Val
210 215 220

Phe Pro Asp Leu Gly Val Val Ala Gly Ala Leu Val Ala Phe Lys His
225 230 235 240

His His His His His
245

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU03/00910

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. [7]: C07K 19/00; A61K 39/00, 39/21, 39/245, 39/29

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Databases: medline, ca, wpids, biosis, biotechabs
Keywords: hydrophobic, epitope, polyepitope, polytope, shuffle, recombine, rearrange, reorder, relocate

Databases: GenPept, PIR, SwissProt, TrEMBL
Sequences: SEQ ID NOs: 1-5

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6,070,126 A (KOKOLUS, W.J. *et al.*), 30 May 2000	
A	WO 00/63693 A (KOKOLUS, W.J.), 26 October 2000	
A	DEAVIN, A.J. *et al.*, "Statistical comparison of established T-cell epitope predictors against a large database of human and murine antigens", Molecular Immunology (1996), vol. 33, no. 2, pages 145-155	

[X] Further documents are listed in the continuation of Box C [X] See patent family annex

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
28 July 2003	- 7 AUG 2003
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer for **STUART BARROW** Telephone No : (02) 6283 2284

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU03/00910

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/47541 A (EPIMMUNE INC.), 5 July 2001	
A	WO 96/03144 A (THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH *et al.*), 8 February 1996	
A	WO 97/05164 A (CSL LIMITED *et al.*), 13 February 1997	

Figure 1

The initial three residues MVD have been introduced due to restriction sites

```
          0.38          1.02          -0.07         0.39          0.55          0.85          -0.06         0.4           0.85
P26A  MVDFLRGRAYGL - PYLFWLAAI – HRCQAIRKK – RRIYDLIEL – VQPPQLTLQV-GLCTLVAML - RLRAEAQVK -IEDPPFNSL -YLLEMLWRL–
          0.18          0.43          0.83          0.2           0.45          0.83          0.32          0.47          0.83
      GQGGSPTAM - AVLLHEESM - IALYLQQNWWTL-RAKFKQLL - SSCSSCPLSKI- TYGPVFMCL-QAKWRLQTL- RPPIFIRRL- VSFIEFVGW-
          0.34          0.52          0.82          0.35          0.53          0.71          0.36
      YPLHEQHGM -  VEITPYKPTW- CLGGLLTMV – EENLLDFVRF - TYSAGIVQI – LLDFVRFMGV -EGGVGWRHW – HHHHHH (SEQ ID NO:94)
```

```
          0.38          1.02          -0.07         0.39          0.85          -0.06         0.4           0.53          0.71
P26B  MVDFLRGRAYGL- PYLFWLAAI – HRCQAIRKK - RRIYDLIEL- GLCTLVAML– RLRAEAQVK- IEDPPFNSL -TYSAGIVQI- LLDFVRFMGV-
          0.36          0.83          0.2           0.45          0.83          0.32          0.47          0.83          0.34
      EGGVGWRHW -  IALYLQQNWWTL - RAKFKQLL - SSCSSCPLSKI – TYGPVFMCL – QAKWRLQTL - RPPIFIRRL - VSFIEFVGW –YPLHEQHGM-
          0.52          0.82          0.35          0.85          0.18          0.43          0.55
      VEITPYKPTW – CLGGLLTMV – EENLLDFVRF - YLLEMLWRL – GQGGSPTAM -  AVLLHEESM –VQPPQLTLQV –HHHHHH (SEQ ID NO:95)
```


Hydrophobicity Index (Fauschere & Pliska)
Polytope P26B
Polytope P26A
Hydrophobicity
1.4
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
Position of 9-mer moving window
5
12
19
26
33
40
47
54
61
68
75
82
89
96
103
110
117
124
131
138
145
152
159
166
173
180
187
194
201
208
215
222
229

Figure 2

Figure 3A gp350/PT26A

```
MEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDLDFGQLTPHTKAVYQPRGAFGGSENAT
                                                  T-help epitope        70
NLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPY
                                                                       140
IKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFN
    T-help epitope                                                     210
ITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCI
                                                                       280
QSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLT
                                                                       350
SGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLNTTGF
                                                                       420
ADPNTTTGVVDFLRGRAYGLPYLFWLAAIHRCQAIRKKRRIYDLIELVQPPQLTLQVGLCTLVAMLRLRAE
     428      B8       A23      B27      B27      B46      A2       A3
AQVKIEDPPFNSLYLLEMLWRLGQGGSPTAMAVLLHEESMIALYLQQNWWTLRAKFKQLLSSCSSCPLSK
       B60      A2       B62      B35      B57/A2      B8       A11

ITYGPVFMCLQAKWRLQTLRPPIFIRRLVSFIEFVGWYPLHEQHGMVEITPYKPTWCLGGLLTMVEENLL
    A24      B8       B7       B58      B35      B44          A2
DFVRFTYSAGIVQILLDFVRFMGVEGGVGWRHWHHHHHH
B44     A24       A2       B44 (SEQ ID NO:96)
```

Figure 3B gp350/PT26B

```
MEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDLDFGQLTPHTKAVYQPRGAFGGSENAT
                                                  T-help epitope        70
NLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPY
                                                                       140
IKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFN
    T-help epitope                                                     210
ITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCI
                                                                       280
QSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLT
                                                                       350
SGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLNTTGF
                                                                       420
ADPNTTTGVVDFLRGRAYGLPYLFWLAAIHRCQAIRKKRRIYDLIELGLCTLVAMLRLRAEAQ VKIEDPPF
     428      B8       A23      B27      B27      A2       A3       B60

NSLTYSAGIVQILLDFVRFMGVEGGVGWRHWIALYLQQNWWTLRAKFKQLLSSCSSCPLSKITYGPVFMC
      A24      A2       B44      B57/A2      B8       A11      A24

LQAKWRLQTLRPPIFIRRLVSFIEFVGWYPLHEQHGMVEITPYKPTWCLGGLLTMVEENLLDFVRFYLLE
    B8       B7       B58      B35      B44      A2       B44

MLWRLGQGGSPTAMAVLLHEESMVQPPQLTLQVHHHHHH (SEQ ID NO:97)
 A2      B62      B35      B46
```

Figure 4A



Figure 4B



Figure 4C



Figure 5


gp350PT26A-ISCOM vaccine (sub. cut)
GLC
YLL
LLD
YLQ
CLG
IFN gamma spots/10^6splenocytes
M1
M2
M3
M4
M5
gp350PT26B-ISCOM vaccine (sub. cut)
GLC
YLL
LLD
YLQ
CLG
IFN gamma spots/10^6splenocytes
150
100
50
0
M1
M2
M3
M4
M5
Positive control - Peptide mix
GLC
YLL
LLD
YLQ
CLG
IFN gamma spots/10^6splenocytes
200
150
100
50
0
M1
M2
M3
M4
M5

Figure 6

EBV-NPCa
1.02 -0.07 0.82 0.98 -0.06 0.4 0.88 0.01 0.45 0.85
SSCSSCPLSKI - HRCQAIRKK - CLGGLLTMV - LTAGFLIFL - RLRAEAQVK - IEDPPFNSL - LLSAWILTA - RRRWRRLTY - PYLFWLAAI - YLLEMLWRL -
0.18 0.64 0.85 0.20 0.67 0.83 0.32 0.71 0.34 0.78
GQGGSPTAM - VMSNTLLSAW - ALLVLYSFA - RAKFKQLL - IALYLQQNW - TYGPVFMCL - QAKWRLQTL - YLQQNWWTL - YPLHEQHGM - CPLSKILL -
0.04
HHHHHH (SEQ ID NO:98)

Figure 7

HIVa

0.98 -0.26 0.44 0.8 -0.16 0.44 0.76 -0.02 0.45 0.71

IPIVAIVALV – RLRPGGKKK – ILKEPVHGV – PLVKLWYQL – RPGGKKKYKL – KYKLKHIVW – TWETWWTEYW – EIKDTKEAL – KRWIILGLNK - KLWVTVYYGV –

0.14 0.47 0.69 0.22 0.48 0.69 0.27 0.5 0.67 0.35 0.53

KIEELRQHL – MTNNPPIPV – VTLWQRPLV – WASRELERF – LLWKGEGAV – YTAFTIPSI – IYQEPFKNLK – SLYNTVATL – AIIRILQQL – AIFQSSMTK – VIYQYMDDL –

0.61 0.36 0.57 0.59 0.57 0.04

LVGPTPVNI – TPQDLNTML – YLAWVPAHK – ALVEICTEM – TLNAWVKVV – HHHHHH (SEQ ID NO:99)

HI values (n=3): 1.16 0.98 1.08 1.08 1.04 1.18 1.19 1.14 1.30 1.32 1.30 1.38 1.39 1.39 1.44 1.46 1.44 1.52 1.55 1.49 1.50 1.54 1.52 1.73 1.20

HIVb

0.44 0.45 0.57 0.14 0.69 0.22 0.8 0.61 0.98 0.5 0.47

ILKEPVHGV – KRWIILGLNK – TLNAWVKVV – KIEELRQHL – YTAFTIPSI – WASRELERF – PLVKLWYQL – LVGPTPVNI – IPIVAIVALV – SLYNTVATL – MTNNPPIPV –

0.48 0.76 0.35 -0.26 0.59 0.71 0.57 0.67 -0.02 0.69

LLWKGEGAV – TWETWWTEYW – AIFQSSMTK – RLRPGGKKK – ALVEICTEM – KLWVTVYYGV – YLAWVPAHK – AIIRILQQL – EIKDTKEAL – VTLWQRPLV –

0.27 0.53 0.36 -0.16 0.44 0.04

IYQEPFKNLK – VIYQYMDDL – TPQDLNTML – RPGGKKKYKL – KYKLKHIVW – HHHHHH (SEQ ID NO:100)

HI values (n=3): 1.46 1.16 1.40 1.05 1.71 1.63 2.39 2.09 1.95 1.45 1.71 1.59 0.85 0.68 1.04 1.87 1.95 1.22 1.34 0.94 1.49 1/16 0.73 0.64 0.32

Figure 8

HCVa

0.94 -0.3 0.61 0.9 -0.07 0.47 0.82 0.15 0.51 0.75

LLFNILGGWV – KTSERSQPR – FLLLADARV – LLFLLLADA – RLGVRATRK – GVAGALVAFK – LPGCSFSIF – RMYVGGVEHR – VAGALVAFK – DLMGYIPLV –

0.33 0.55 0.73 0.34 0.56 0.72 0.34 0.56 0.68 0.35

LIFCHSKKK – ILAGYGAGV – HMWNFISGI – QLFTFSPRR – VGIYLLPNR – FWAKHMWNF – YLVTRHADV – LSAFSLHSY – WMNRLIAFA – YLLPRRGPRL –

0.58 0.67 0.41 0.61 0.67 0.44 0.04

YLVAYQATV – RLIVFPDLGV – TLGFGAYMSK – IPFYGKAI – VLVGGVLAA – CTCGSSDLY – HHHHHH (SEQ ID NO:101)

HI values (n=3): 1.25 1.21 1.44 1.3 1.22 1.44 1.48 1.41 1.59 1.63 1.61 1.62 1.63 1.62 1.62 1.62 1.58 1.59 1.61 1.60 1.66 1.69 1.69 1.72 1.15

HCVb

0.34 0.68 0.44 0.56 0.55 0.33 0.73 0.61 0.9 0.56

YLVTRHADV – WMNRLIAFA – CTCGSSDLY – VGIYLLPNR – ILAGYGAGV – LIFCHSKKK – HMWNFISG – IFLLLADARV – LLFLLLADA – LSAFSLHSY –

0.47 -0.3 -0.07 0.75 0.67 0.94 0.58 0.35 0.72 0.34

GVAGALVAFK – KTSERSQPR – RLGVRATRK – DLMGYIPLV – VLVGGVLAA – LLFNILGGWV – YLVAYQATV – YLLPRRGPRL – FWAKHMWNF – QLFTFSPRR –

0.82 0.61 0.15 0.41 0.67 0.51 0.04

LPGCSFSIF – IPFYGKAI – RMYVGGVEHR – TLGFGAYMSK – RLIVFPDLGV – VAGALVAFK – HHHHHH (SEQ ID NO:102)

HI values (n=3): 1.46 1.68 1.55 1.44 1.61 1.67 2.24 2.07 1.93 0.73 0.10 0.38 1.35 2.36 2.19 1.87 1.65 1.41 1.88 1.77 1.58 1.17 1.23 1.59 1.22

Figure 9



Figure 10